Stem definition | Drug id | CAS RN |
---|---|---|
estrogens | 1057 | 50-28-2 |
Dose | Unit | Route |
---|---|---|
0.30 | mg | N |
2 | mg | O |
1 | mg | P |
0.30 | mg | P |
5 | mg | R |
50 | mcg | TD |
1 | mg | TD |
1.53 | mg | TD |
25 | mcg | V |
7.50 | mcg | V |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.01 mg/mL | Bocci G, Oprea TI, Benet LZ |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.84 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 5 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.20 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.70 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
July 23, 1975 | FDA | BRISTOL MYERS SQUIBB | |
Nov. 25, 2011 | PMDA | Shiseido Company, Limited |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Product adhesion issue | 4001.61 | 9.76 | 1019 | 99585 | 3700 | 63384718 |
Hot flush | 939.96 | 9.76 | 722 | 99882 | 50437 | 63337981 |
Application site rash | 857.54 | 9.76 | 266 | 100338 | 2232 | 63386186 |
Application site erythema | 560.34 | 9.76 | 230 | 100374 | 4605 | 63383813 |
Application site pruritus | 494.19 | 9.76 | 199 | 100405 | 3785 | 63384633 |
Product quality issue | 459.62 | 9.76 | 411 | 100193 | 35454 | 63352964 |
Application site irritation | 404.07 | 9.76 | 138 | 100466 | 1612 | 63386806 |
Meningioma | 403.73 | 9.76 | 171 | 100433 | 3714 | 63384704 |
Vulvovaginal discomfort | 351.98 | 9.76 | 135 | 100469 | 2243 | 63386175 |
Pemphigus | 244.49 | 9.76 | 11 | 100593 | 183715 | 63204703 |
Application site reaction | 228.82 | 9.76 | 73 | 100531 | 677 | 63387741 |
Wrong technique in product usage process | 225.75 | 9.76 | 376 | 100228 | 61964 | 63326454 |
Menopausal symptoms | 209.09 | 9.76 | 94 | 100510 | 2367 | 63386051 |
Vulvovaginal pain | 205.77 | 9.76 | 96 | 100508 | 2639 | 63385779 |
Schizoaffective disorder | 201.81 | 9.76 | 103 | 100501 | 3459 | 63384959 |
Hand deformity | 195.59 | 9.76 | 15 | 100589 | 159442 | 63228976 |
Vulvovaginal burning sensation | 186.99 | 9.76 | 83 | 100521 | 2026 | 63386392 |
Glossodynia | 184.16 | 9.76 | 31 | 100573 | 178845 | 63209573 |
Pneumonia viral | 168.05 | 9.76 | 122 | 100482 | 7800 | 63380618 |
Death | 160.74 | 9.76 | 215 | 100389 | 374166 | 63014252 |
Breast tenderness | 159.99 | 9.76 | 77 | 100527 | 2273 | 63386145 |
Systemic lupus erythematosus | 157.36 | 9.76 | 67 | 100537 | 208851 | 63179567 |
Vaginal haemorrhage | 156.22 | 9.76 | 205 | 100399 | 27282 | 63361136 |
Vulvovaginal dryness | 156.02 | 9.76 | 81 | 100523 | 2820 | 63385598 |
Application site pain | 154.06 | 9.76 | 91 | 100513 | 4091 | 63384327 |
Product physical issue | 149.30 | 9.76 | 95 | 100509 | 4885 | 63383533 |
Anti-cyclic citrullinated peptide antibody positive | 148.13 | 9.76 | 9 | 100595 | 116203 | 63272215 |
Blood oestrogen decreased | 146.80 | 9.76 | 41 | 100563 | 227 | 63388191 |
Application site vesicles | 135.40 | 9.76 | 59 | 100545 | 1376 | 63387042 |
Toxicity to various agents | 134.98 | 9.76 | 116 | 100488 | 247134 | 63141284 |
Wound | 131.77 | 9.76 | 47 | 100557 | 163216 | 63225202 |
Soft tissue disorder | 131.68 | 9.76 | 84 | 100520 | 4338 | 63384080 |
Maternal exposure during pregnancy | 129.20 | 9.76 | 96 | 100508 | 219966 | 63168452 |
Product complaint | 126.24 | 9.76 | 127 | 100477 | 12682 | 63375736 |
Pericarditis | 124.44 | 9.76 | 28 | 100576 | 131551 | 63256867 |
Ovarian hyperstimulation syndrome | 121.40 | 9.76 | 77 | 100527 | 3937 | 63384481 |
Arthropathy | 120.02 | 9.76 | 117 | 100487 | 234675 | 63153743 |
Contraindicated product administered | 116.50 | 9.76 | 104 | 100500 | 217544 | 63170874 |
Application site urticaria | 116.08 | 9.76 | 34 | 100570 | 229 | 63388189 |
Feeling abnormal | 115.75 | 9.76 | 504 | 100100 | 147888 | 63240530 |
Rheumatoid factor positive | 112.40 | 9.76 | 5 | 100599 | 84401 | 63304017 |
Application site burn | 111.57 | 9.76 | 44 | 100560 | 790 | 63387628 |
Vaginal discharge | 111.07 | 9.76 | 102 | 100502 | 9096 | 63379322 |
Product substitution issue | 109.57 | 9.76 | 131 | 100473 | 15865 | 63372553 |
Colitis microscopic | 107.82 | 9.76 | 101 | 100503 | 9238 | 63379180 |
Migraine | 107.26 | 9.76 | 384 | 100220 | 102962 | 63285456 |
Hormone level abnormal | 104.71 | 9.76 | 59 | 100545 | 2424 | 63385994 |
Device adhesion issue | 104.13 | 9.76 | 77 | 100527 | 5064 | 63383354 |
Duodenal ulcer perforation | 99.43 | 9.76 | 11 | 100593 | 87198 | 63301220 |
Hysterectomy | 95.11 | 9.76 | 95 | 100509 | 9404 | 63379014 |
Helicobacter infection | 93.43 | 9.76 | 17 | 100587 | 92768 | 63295650 |
Exposure during pregnancy | 91.07 | 9.76 | 68 | 100536 | 155479 | 63232939 |
Postmenopausal haemorrhage | 90.60 | 9.76 | 51 | 100553 | 2091 | 63386327 |
Incorrect dose administered by product | 88.15 | 9.76 | 26 | 100578 | 180 | 63388238 |
Infusion related reaction | 86.26 | 9.76 | 161 | 100443 | 245360 | 63143058 |
Drug abuse | 83.05 | 9.76 | 9 | 100595 | 72509 | 63315909 |
General physical health deterioration | 81.96 | 9.76 | 120 | 100484 | 201282 | 63187136 |
Neutropenia | 81.79 | 9.76 | 94 | 100510 | 174911 | 63213507 |
Salpingo-oophorectomy unilateral | 79.16 | 9.76 | 35 | 100569 | 846 | 63387572 |
Completed suicide | 78.64 | 9.76 | 69 | 100535 | 145604 | 63242814 |
Vaginal infection | 78.63 | 9.76 | 77 | 100527 | 7441 | 63380977 |
Skin reaction | 78.62 | 9.76 | 107 | 100497 | 14742 | 63373676 |
Febrile neutropenia | 75.71 | 9.76 | 47 | 100557 | 118402 | 63270016 |
Device material issue | 75.18 | 9.76 | 24 | 100580 | 223 | 63388195 |
Product dose omission issue | 74.73 | 9.76 | 630 | 99974 | 233683 | 63154735 |
Acute kidney injury | 72.73 | 9.76 | 197 | 100407 | 263218 | 63125200 |
Application site hypersensitivity | 71.45 | 9.76 | 23 | 100581 | 220 | 63388198 |
Vaginal odour | 71.03 | 9.76 | 28 | 100576 | 502 | 63387916 |
Sinusitis fungal | 70.49 | 9.76 | 41 | 100563 | 1790 | 63386628 |
Treatment failure | 70.35 | 9.76 | 130 | 100474 | 198913 | 63189505 |
Intermenstrual bleeding | 69.82 | 9.76 | 74 | 100530 | 7852 | 63380566 |
Headache | 69.82 | 9.76 | 1398 | 99206 | 631843 | 62756575 |
Glaucoma | 69.69 | 9.76 | 115 | 100489 | 18790 | 63369628 |
No adverse event | 68.35 | 9.76 | 181 | 100423 | 41224 | 63347194 |
Depression | 66.76 | 9.76 | 536 | 100068 | 195956 | 63192462 |
Bronchitis | 66.57 | 9.76 | 381 | 100223 | 124554 | 63263864 |
Fungal infection | 65.82 | 9.76 | 166 | 100438 | 36708 | 63351710 |
Intentional overdose | 65.78 | 9.76 | 18 | 100586 | 74134 | 63314284 |
Skin irritation | 65.45 | 9.76 | 79 | 100525 | 9662 | 63378756 |
Sputum increased | 64.15 | 9.76 | 43 | 100561 | 2416 | 63386002 |
Insomnia | 64.04 | 9.76 | 570 | 100034 | 214682 | 63173736 |
Thrombocytopenia | 63.52 | 9.76 | 88 | 100516 | 151069 | 63237349 |
Embolism venous | 63.34 | 9.76 | 47 | 100557 | 3107 | 63385311 |
Vulvovaginal pruritus | 62.17 | 9.76 | 47 | 100557 | 3196 | 63385222 |
Incorrect dose administered by device | 62.03 | 9.76 | 53 | 100551 | 4295 | 63384123 |
Breast cancer | 61.92 | 9.76 | 193 | 100411 | 48190 | 63340228 |
Blood oestrogen increased | 60.74 | 9.76 | 17 | 100587 | 95 | 63388323 |
Liver function test abnormal | 60.56 | 9.76 | 191 | 100413 | 47990 | 63340428 |
Diverticulitis | 60.37 | 9.76 | 168 | 100436 | 39389 | 63349029 |
Pancytopenia | 59.85 | 9.76 | 40 | 100564 | 96893 | 63291525 |
Herpes zoster | 59.66 | 9.76 | 274 | 100330 | 82188 | 63306230 |
Cardiac arrest | 58.75 | 9.76 | 37 | 100567 | 92508 | 63295910 |
Oestrogen receptor assay positive | 58.11 | 9.76 | 24 | 100580 | 488 | 63387930 |
Hyperkalaemia | 56.62 | 9.76 | 9 | 100595 | 54194 | 63334224 |
Application site scar | 56.09 | 9.76 | 19 | 100585 | 216 | 63388202 |
Thyroid disorder | 55.57 | 9.76 | 92 | 100512 | 15070 | 63373348 |
Folliculitis | 55.42 | 9.76 | 21 | 100583 | 70296 | 63318122 |
Pyrexia | 54.97 | 9.76 | 479 | 100125 | 469999 | 62918419 |
Incorrect dose administered | 54.83 | 9.76 | 214 | 100390 | 59754 | 63328664 |
Drug level increased | 54.53 | 9.76 | 115 | 100489 | 22621 | 63365797 |
Respiratory symptom | 54.41 | 9.76 | 44 | 100560 | 3303 | 63385115 |
Sleep disorder due to general medical condition, insomnia type | 53.80 | 9.76 | 9 | 100595 | 52208 | 63336210 |
Swelling | 53.68 | 9.76 | 239 | 100365 | 275139 | 63113279 |
Vaginal erosion | 53.65 | 9.76 | 12 | 100592 | 20 | 63388398 |
Product size issue | 51.71 | 9.76 | 20 | 100584 | 340 | 63388078 |
Drug intolerance | 50.93 | 9.76 | 284 | 100320 | 308377 | 63080041 |
Abdominal discomfort | 50.40 | 9.76 | 300 | 100304 | 320585 | 63067833 |
Night sweats | 50.28 | 9.76 | 181 | 100423 | 48633 | 63339785 |
Device use issue | 50.16 | 9.76 | 38 | 100566 | 2592 | 63385826 |
Cardiac failure | 49.59 | 9.76 | 41 | 100563 | 89101 | 63299317 |
Sepsis | 48.95 | 9.76 | 106 | 100498 | 153017 | 63235401 |
Application site swelling | 48.85 | 9.76 | 22 | 100582 | 556 | 63387862 |
Fibromyalgia | 48.71 | 9.76 | 254 | 100350 | 80166 | 63308252 |
Hypotension | 48.20 | 9.76 | 245 | 100359 | 272359 | 63116059 |
Liver injury | 47.82 | 9.76 | 18 | 100586 | 60502 | 63327916 |
Progesterone receptor assay positive | 47.68 | 9.76 | 19 | 100585 | 351 | 63388067 |
Application site discolouration | 47.26 | 9.76 | 24 | 100580 | 797 | 63387621 |
Oral pain | 46.73 | 9.76 | 124 | 100480 | 28270 | 63360148 |
Arthritis | 46.54 | 9.76 | 329 | 100275 | 115592 | 63272826 |
Product packaging issue | 46.42 | 9.76 | 27 | 100577 | 1179 | 63387239 |
Breast cancer in situ | 45.78 | 9.76 | 29 | 100575 | 1479 | 63386939 |
Ophthalmic vein thrombosis | 45.15 | 9.76 | 16 | 100588 | 210 | 63388208 |
Product odour abnormal | 44.62 | 9.76 | 27 | 100577 | 1269 | 63387149 |
Hyperhidrosis | 44.43 | 9.76 | 308 | 100296 | 107528 | 63280890 |
Application site dermatitis | 44.24 | 9.76 | 15 | 100589 | 171 | 63388247 |
Fibrocystic breast disease | 44.07 | 9.76 | 26 | 100578 | 1166 | 63387252 |
Sleep apnoea syndrome | 43.73 | 9.76 | 123 | 100481 | 29010 | 63359408 |
Breast enlargement | 43.62 | 9.76 | 29 | 100575 | 1607 | 63386811 |
Application site erosion | 43.55 | 9.76 | 15 | 100589 | 180 | 63388238 |
Colitis ischaemic | 43.38 | 9.76 | 68 | 100536 | 10640 | 63377778 |
Application site inflammation | 43.35 | 9.76 | 18 | 100586 | 371 | 63388047 |
Therapeutic product effect decreased | 43.07 | 9.76 | 159 | 100445 | 193028 | 63195390 |
Multiple organ dysfunction syndrome | 43.00 | 9.76 | 18 | 100586 | 56734 | 63331684 |
Disease progression | 42.62 | 9.76 | 81 | 100523 | 122677 | 63265741 |
Mucosal inflammation | 42.36 | 9.76 | 11 | 100593 | 46917 | 63341501 |
Musculoskeletal stiffness | 41.78 | 9.76 | 151 | 100453 | 184467 | 63203951 |
Muscle spasms | 41.63 | 9.76 | 404 | 100200 | 155746 | 63232672 |
Mood swings | 41.12 | 9.76 | 90 | 100514 | 18158 | 63370260 |
Diastolic dysfunction | 41.08 | 9.76 | 51 | 100553 | 6420 | 63381998 |
Cardio-respiratory arrest | 40.85 | 9.76 | 22 | 100582 | 59937 | 63328481 |
Bladder prolapse | 40.79 | 9.76 | 31 | 100573 | 2125 | 63386293 |
Disease recurrence | 40.77 | 9.76 | 117 | 100487 | 27913 | 63360505 |
Malignant neoplasm progression | 40.67 | 9.76 | 42 | 100562 | 82079 | 63306339 |
Alopecia | 40.10 | 9.76 | 342 | 100262 | 337194 | 63051224 |
Platelet count decreased | 39.98 | 9.76 | 77 | 100527 | 116045 | 63272373 |
Product shape issue | 39.85 | 9.76 | 12 | 100592 | 90 | 63388328 |
Butterfly rash | 39.19 | 9.76 | 28 | 100576 | 1745 | 63386673 |
Vulvovaginal mycotic infection | 38.80 | 9.76 | 46 | 100558 | 5520 | 63382898 |
Nasal polyps | 37.38 | 9.76 | 47 | 100557 | 5992 | 63382426 |
Therapeutic response unexpected | 37.25 | 9.76 | 88 | 100516 | 18671 | 63369747 |
Breast pain | 37.22 | 9.76 | 57 | 100547 | 8741 | 63379677 |
Discomfort | 36.49 | 9.76 | 139 | 100465 | 167235 | 63221183 |
Diverticulum | 36.45 | 9.76 | 67 | 100537 | 11924 | 63376494 |
Lower respiratory tract infection | 36.43 | 9.76 | 99 | 100505 | 132208 | 63256210 |
Muscle injury | 36.41 | 9.76 | 30 | 100574 | 65315 | 63323103 |
Oestradiol increased | 36.13 | 9.76 | 11 | 100593 | 86 | 63388332 |
Wrong technique in device usage process | 36.05 | 9.76 | 36 | 100568 | 3562 | 63384856 |
Product packaging quantity issue | 36.02 | 9.76 | 24 | 100580 | 1335 | 63387083 |
Joint swelling | 35.86 | 9.76 | 339 | 100265 | 327327 | 63061091 |
Influenza like illness | 35.71 | 9.76 | 204 | 100400 | 66620 | 63321798 |
Respiratory failure | 35.54 | 9.76 | 67 | 100537 | 101791 | 63286627 |
Dyspareunia | 35.18 | 9.76 | 30 | 100574 | 2425 | 63385993 |
Type 2 diabetes mellitus | 34.75 | 9.76 | 30 | 100574 | 63838 | 63324580 |
Dermatitis contact | 34.08 | 9.76 | 62 | 100542 | 10946 | 63377472 |
Placenta accreta | 34.05 | 9.76 | 13 | 100591 | 213 | 63388205 |
Endometrial cancer | 33.67 | 9.76 | 33 | 100571 | 3192 | 63385226 |
Application site dryness | 33.62 | 9.76 | 12 | 100592 | 161 | 63388257 |
Eczema | 33.48 | 9.76 | 120 | 100484 | 32171 | 63356247 |
Osteopenia | 33.16 | 9.76 | 87 | 100517 | 19698 | 63368720 |
Abdominal distension | 33.12 | 9.76 | 243 | 100361 | 86372 | 63302046 |
Septic shock | 33.08 | 9.76 | 34 | 100570 | 66595 | 63321823 |
Vision blurred | 32.96 | 9.76 | 254 | 100350 | 91670 | 63296748 |
Lactic acidosis | 32.65 | 9.76 | 10 | 100594 | 38277 | 63350141 |
Oestradiol decreased | 32.54 | 9.76 | 8 | 100596 | 24 | 63388394 |
Overdose | 32.52 | 9.76 | 85 | 100519 | 114993 | 63273425 |
Vulvovaginal injury | 32.34 | 9.76 | 16 | 100588 | 502 | 63387916 |
Anxiety | 32.29 | 9.76 | 504 | 100100 | 217037 | 63171381 |
Hepatic enzyme increased | 31.81 | 9.76 | 189 | 100415 | 202139 | 63186279 |
Tricuspid valve incompetence | 31.69 | 9.76 | 71 | 100533 | 14550 | 63373868 |
Application site exfoliation | 31.28 | 9.76 | 15 | 100589 | 439 | 63387979 |
Hepatic function abnormal | 31.14 | 9.76 | 10 | 100594 | 37132 | 63351286 |
Mobility decreased | 30.91 | 9.76 | 94 | 100510 | 121065 | 63267353 |
Tinnitus | 30.84 | 9.76 | 125 | 100479 | 35503 | 63352915 |
Palpitations | 30.65 | 9.76 | 293 | 100311 | 112477 | 63275941 |
Hypoglycaemia | 30.56 | 9.76 | 30 | 100574 | 60035 | 63328383 |
Irritability | 30.52 | 9.76 | 115 | 100489 | 31579 | 63356839 |
Confusional state | 30.11 | 9.76 | 235 | 100369 | 236145 | 63152273 |
Spinal operation | 30.06 | 9.76 | 50 | 100554 | 8221 | 63380197 |
Rectal prolapse | 29.99 | 9.76 | 25 | 100579 | 1958 | 63386460 |
Decreased appetite | 29.96 | 9.76 | 254 | 100350 | 250798 | 63137620 |
Endometrial stromal sarcoma | 29.84 | 9.76 | 7 | 100597 | 16 | 63388402 |
Stomatitis | 29.73 | 9.76 | 116 | 100488 | 138609 | 63249809 |
Lung disorder | 29.54 | 9.76 | 33 | 100571 | 62228 | 63326190 |
Surgery | 29.51 | 9.76 | 124 | 100480 | 35788 | 63352630 |
Endometrial hyperplasia | 29.44 | 9.76 | 18 | 100586 | 862 | 63387556 |
Female genital tract fistula | 29.24 | 9.76 | 47 | 100557 | 7512 | 63380906 |
Renal failure | 28.80 | 9.76 | 93 | 100511 | 117559 | 63270859 |
Endometrial cancer stage I | 28.57 | 9.76 | 12 | 100592 | 255 | 63388163 |
Coma | 28.52 | 9.76 | 36 | 100568 | 64328 | 63324090 |
Delirium | 28.41 | 9.76 | 23 | 100581 | 50518 | 63337900 |
Cholestasis | 28.35 | 9.76 | 6 | 100598 | 29428 | 63358990 |
Renal impairment | 27.53 | 9.76 | 62 | 100542 | 88293 | 63300125 |
White blood cell count decreased | 27.51 | 9.76 | 120 | 100484 | 138984 | 63249434 |
Pseudoprecocious puberty | 27.25 | 9.76 | 5 | 100599 | 0 | 63388418 |
Application site ulcer | 27.08 | 9.76 | 9 | 100595 | 96 | 63388322 |
Nipple pain | 26.92 | 9.76 | 12 | 100592 | 296 | 63388122 |
Skin burning sensation | 26.67 | 9.76 | 61 | 100543 | 12673 | 63375745 |
Stress | 26.58 | 9.76 | 190 | 100414 | 66977 | 63321441 |
Therapy non-responder | 26.41 | 9.76 | 50 | 100554 | 75851 | 63312567 |
Blood creatinine increased | 26.28 | 9.76 | 63 | 100541 | 87781 | 63300637 |
Bone marrow failure | 26.18 | 9.76 | 7 | 100597 | 29283 | 63359135 |
Application site discharge | 26.02 | 9.76 | 10 | 100594 | 167 | 63388251 |
Emphysema | 25.85 | 9.76 | 55 | 100549 | 10883 | 63377535 |
Gastrooesophageal reflux disease | 25.74 | 9.76 | 248 | 100356 | 95391 | 63293027 |
Spinal stenosis | 25.39 | 9.76 | 66 | 100538 | 14859 | 63373559 |
Periodontal disease | 25.39 | 9.76 | 21 | 100583 | 1627 | 63386791 |
Poor quality product administered | 25.24 | 9.76 | 28 | 100576 | 3128 | 63385290 |
Pre-existing condition improved | 24.98 | 9.76 | 46 | 100558 | 8198 | 63380220 |
Red blood cell sedimentation rate increased | 24.74 | 9.76 | 20 | 100584 | 43962 | 63344456 |
Crying | 24.41 | 9.76 | 87 | 100517 | 23256 | 63365162 |
Blood cholesterol increased | 24.41 | 9.76 | 242 | 100362 | 93790 | 63294628 |
Photosensitivity reaction | 24.19 | 9.76 | 65 | 100539 | 14929 | 63373489 |
Hypothalamo-pituitary disorder | 24.17 | 9.76 | 15 | 100589 | 738 | 63387680 |
Therapeutic product effect increased | 24.16 | 9.76 | 18 | 100586 | 1197 | 63387221 |
Vulvovaginal erythema | 24.10 | 9.76 | 11 | 100593 | 287 | 63388131 |
Condition aggravated | 24.03 | 9.76 | 471 | 100133 | 401746 | 62986672 |
Application site discomfort | 23.98 | 9.76 | 12 | 100592 | 386 | 63388032 |
Bradycardia | 23.96 | 9.76 | 50 | 100554 | 73177 | 63315241 |
Haemoglobin decreased | 23.88 | 9.76 | 134 | 100470 | 145351 | 63243067 |
Carpal tunnel syndrome | 23.87 | 9.76 | 80 | 100524 | 20737 | 63367681 |
Feeling hot | 23.87 | 9.76 | 149 | 100455 | 50205 | 63338213 |
Incorrect product administration duration | 23.84 | 9.76 | 55 | 100549 | 11491 | 63376927 |
Insulin-like growth factor increased | 23.81 | 9.76 | 16 | 100588 | 903 | 63387515 |
Loss of personal independence in daily activities | 23.74 | 9.76 | 77 | 100527 | 97213 | 63291205 |
Gastrointestinal haemorrhage | 23.67 | 9.76 | 59 | 100545 | 81117 | 63307301 |
Libido decreased | 23.63 | 9.76 | 25 | 100579 | 2647 | 63385771 |
Bone density abnormal | 23.55 | 9.76 | 28 | 100576 | 3370 | 63385048 |
Endometrial hypertrophy | 23.45 | 9.76 | 11 | 100593 | 306 | 63388112 |
Meniscus injury | 23.22 | 9.76 | 41 | 100563 | 7073 | 63381345 |
Live birth | 23.15 | 9.76 | 6 | 100598 | 25624 | 63362794 |
Suicide attempt | 23.12 | 9.76 | 38 | 100566 | 60880 | 63327538 |
Hyponatraemia | 23.06 | 9.76 | 95 | 100509 | 111805 | 63276613 |
Vulvovaginal swelling | 22.98 | 9.76 | 13 | 100591 | 538 | 63387880 |
Hypoxia | 22.97 | 9.76 | 37 | 100567 | 59755 | 63328663 |
Vomiting | 22.85 | 9.76 | 694 | 99910 | 558923 | 62829495 |
Psoriasis | 22.67 | 9.76 | 224 | 100380 | 86733 | 63301685 |
Pneumonia | 22.65 | 9.76 | 551 | 100053 | 456216 | 62932202 |
Uterine leiomyoma | 22.61 | 9.76 | 47 | 100557 | 9151 | 63379267 |
Breast mass | 22.50 | 9.76 | 43 | 100561 | 7879 | 63380539 |
Sinus rhythm | 22.41 | 9.76 | 15 | 100589 | 841 | 63387577 |
Memory impairment | 22.26 | 9.76 | 258 | 100346 | 104000 | 63284418 |
Cystocele | 22.22 | 9.76 | 17 | 100587 | 1177 | 63387241 |
Sinusitis | 22.09 | 9.76 | 492 | 100112 | 226161 | 63162257 |
Pleural effusion | 21.90 | 9.76 | 75 | 100529 | 93135 | 63295283 |
Uterine polyp | 21.44 | 9.76 | 21 | 100583 | 2029 | 63386389 |
Ventricular dyskinesia | 21.36 | 9.76 | 8 | 100596 | 124 | 63388294 |
Breast discomfort | 21.29 | 9.76 | 12 | 100592 | 493 | 63387925 |
Metabolic acidosis | 21.26 | 9.76 | 24 | 100580 | 45045 | 63343373 |
Neoplasm progression | 21.20 | 9.76 | 16 | 100588 | 36412 | 63352006 |
Breast calcifications | 21.20 | 9.76 | 17 | 100587 | 1261 | 63387157 |
Impaired healing | 21.17 | 9.76 | 87 | 100517 | 102455 | 63285963 |
Chronic sinusitis | 21.04 | 9.76 | 56 | 100548 | 12787 | 63375631 |
Hypokalaemia | 20.85 | 9.76 | 89 | 100515 | 103715 | 63284703 |
Altered state of consciousness | 20.79 | 9.76 | 7 | 100597 | 25223 | 63363195 |
Stress urinary incontinence | 20.77 | 9.76 | 22 | 100582 | 2333 | 63386085 |
Drug ineffective | 20.74 | 9.76 | 1922 | 98682 | 1042843 | 62345575 |
Gastrointestinal disorder | 20.40 | 9.76 | 123 | 100481 | 131116 | 63257302 |
Atrophic vulvovaginitis | 20.17 | 9.76 | 19 | 100585 | 1749 | 63386669 |
Histamine intolerance | 20.16 | 9.76 | 6 | 100598 | 43 | 63388375 |
Pulmonary fibrosis | 20.12 | 9.76 | 20 | 100584 | 39789 | 63348629 |
Oral herpes | 19.86 | 9.76 | 88 | 100516 | 25986 | 63362432 |
Vessel puncture site bruise | 19.81 | 9.76 | 11 | 100593 | 439 | 63387979 |
Hiatus hernia | 19.68 | 9.76 | 77 | 100527 | 21517 | 63366901 |
Interstitial lung disease | 19.65 | 9.76 | 43 | 100561 | 61865 | 63326553 |
Device expulsion | 19.49 | 9.76 | 16 | 100588 | 34906 | 63353512 |
Intervertebral disc degeneration | 19.43 | 9.76 | 62 | 100542 | 15670 | 63372748 |
Burning sensation | 19.31 | 9.76 | 150 | 100454 | 54257 | 63334161 |
Product availability issue | 19.29 | 9.76 | 28 | 100576 | 4093 | 63384325 |
Muscle fatigue | 19.23 | 9.76 | 22 | 100582 | 2542 | 63385876 |
Breast cancer female | 19.14 | 9.76 | 56 | 100548 | 13503 | 63374915 |
Dermal absorption impaired | 19.06 | 9.76 | 6 | 100598 | 53 | 63388365 |
Expulsion of medication | 19.04 | 9.76 | 5 | 100599 | 21 | 63388397 |
Lymphogranuloma venereum | 19.03 | 9.76 | 4 | 100600 | 4 | 63388414 |
Corticosteroid binding globulin increased | 19.03 | 9.76 | 4 | 100600 | 4 | 63388414 |
Vaginal disorder | 19.01 | 9.76 | 13 | 100591 | 755 | 63387663 |
Hypomagnesaemia | 18.92 | 9.76 | 11 | 100593 | 28726 | 63359692 |
Retinal vein occlusion | 18.86 | 9.76 | 20 | 100584 | 2123 | 63386295 |
Application site infection | 18.77 | 9.76 | 6 | 100598 | 56 | 63388362 |
Withdrawal bleed | 18.49 | 9.76 | 6 | 100598 | 59 | 63388359 |
Intestinal polyp | 18.49 | 9.76 | 17 | 100587 | 1518 | 63386900 |
Thyroxine decreased | 18.44 | 9.76 | 12 | 100592 | 641 | 63387777 |
Product colour issue | 18.38 | 9.76 | 12 | 100592 | 645 | 63387773 |
Paraesthesia | 18.33 | 9.76 | 350 | 100254 | 156616 | 63231802 |
Anaemia | 18.31 | 9.76 | 341 | 100263 | 293089 | 63095329 |
Vitamin D decreased | 18.16 | 9.76 | 46 | 100558 | 10196 | 63378222 |
Intentional self-injury | 18.13 | 9.76 | 9 | 100595 | 25678 | 63362740 |
Neutrophil count decreased | 18.05 | 9.76 | 39 | 100565 | 56367 | 63332051 |
Palmar-plantar erythrodysaesthesia syndrome | 17.92 | 9.76 | 7 | 100597 | 23008 | 63365410 |
Injection site inflammation | 17.83 | 9.76 | 26 | 100578 | 3817 | 63384601 |
Ill-defined disorder | 17.74 | 9.76 | 68 | 100536 | 81687 | 63306731 |
Product taste abnormal | 17.68 | 9.76 | 19 | 100585 | 2048 | 63386370 |
Right ventricular failure | 17.62 | 9.76 | 3 | 100601 | 17185 | 63371233 |
Breast hyperplasia | 17.61 | 9.76 | 9 | 100595 | 303 | 63388115 |
International normalised ratio increased | 17.58 | 9.76 | 29 | 100575 | 46396 | 63342022 |
Periorbital oedema | 17.58 | 9.76 | 32 | 100572 | 5652 | 63382766 |
Prescribed overdose | 17.44 | 9.76 | 17 | 100587 | 34136 | 63354282 |
Low density lipoprotein increased | 17.44 | 9.76 | 34 | 100570 | 6323 | 63382095 |
Thermal burn | 17.40 | 9.76 | 33 | 100571 | 6013 | 63382405 |
Rectocele | 17.36 | 9.76 | 14 | 100590 | 1047 | 63387371 |
Product prescribing error | 17.29 | 9.76 | 85 | 100519 | 26204 | 63362214 |
Respiratory distress | 17.22 | 9.76 | 17 | 100587 | 33934 | 63354484 |
Atypical haemolytic uraemic syndrome | 17.16 | 9.76 | 12 | 100592 | 723 | 63387695 |
Osteoporosis | 17.09 | 9.76 | 152 | 100452 | 57186 | 63331232 |
Pregnancy | 16.96 | 9.76 | 20 | 100584 | 36816 | 63351602 |
Shock | 16.89 | 9.76 | 8 | 100596 | 23455 | 63364963 |
Emotional disorder | 16.77 | 9.76 | 53 | 100551 | 13326 | 63375092 |
Head discomfort | 16.68 | 9.76 | 53 | 100551 | 13362 | 63375056 |
Craniopharyngioma | 16.57 | 9.76 | 7 | 100597 | 151 | 63388267 |
Pituitary tumour | 16.56 | 9.76 | 13 | 100591 | 935 | 63387483 |
Prosopagnosia | 16.55 | 9.76 | 5 | 100599 | 38 | 63388380 |
Endometriosis | 16.51 | 9.76 | 30 | 100574 | 5290 | 63383128 |
Poor quality sleep | 16.51 | 9.76 | 69 | 100535 | 19866 | 63368552 |
Creatinine renal clearance decreased | 16.38 | 9.76 | 3 | 100601 | 16305 | 63372113 |
Abnormal dreams | 16.37 | 9.76 | 45 | 100559 | 10471 | 63377947 |
Bacterial vulvovaginitis | 16.30 | 9.76 | 12 | 100592 | 784 | 63387634 |
Drug resistance | 16.24 | 9.76 | 8 | 100596 | 22925 | 63365493 |
Breast disorder | 16.15 | 9.76 | 20 | 100584 | 2510 | 63385908 |
Hip arthroplasty | 16.04 | 9.76 | 32 | 100572 | 47614 | 63340804 |
Ovarian atrophy | 16.02 | 9.76 | 6 | 100598 | 93 | 63388325 |
Pelvic infection | 16.01 | 9.76 | 9 | 100595 | 368 | 63388050 |
COVID-19 | 15.99 | 9.76 | 260 | 100344 | 112843 | 63275575 |
Spinal osteoarthritis | 15.81 | 9.76 | 59 | 100545 | 16127 | 63372291 |
Acute respiratory distress syndrome | 15.50 | 9.76 | 9 | 100595 | 23525 | 63364893 |
Uterine haemorrhage | 15.46 | 9.76 | 25 | 100579 | 4016 | 63384402 |
Dyspnoea | 15.46 | 9.76 | 874 | 99730 | 660439 | 62727979 |
Soft tissue swelling | 15.42 | 9.76 | 14 | 100590 | 1230 | 63387188 |
Infusion site erythema | 15.32 | 9.76 | 47 | 100557 | 11632 | 63376786 |
Pericardial effusion | 15.30 | 9.76 | 15 | 100589 | 30043 | 63358375 |
Blood pressure increased | 15.22 | 9.76 | 350 | 100254 | 161712 | 63226706 |
Myalgia | 15.20 | 9.76 | 321 | 100283 | 146208 | 63242210 |
Back pain | 15.19 | 9.76 | 536 | 100068 | 263609 | 63124809 |
Inflammation | 15.05 | 9.76 | 73 | 100531 | 82200 | 63306218 |
Blood pressure systolic abnormal | 14.96 | 9.76 | 51 | 100553 | 13335 | 63375083 |
Aptyalism | 14.95 | 9.76 | 10 | 100594 | 560 | 63387858 |
Drug reaction with eosinophilia and systemic symptoms | 14.91 | 9.76 | 19 | 100585 | 33817 | 63354601 |
Umbilical hernia | 14.88 | 9.76 | 21 | 100583 | 2993 | 63385425 |
Transfusion | 14.86 | 9.76 | 3 | 100601 | 15214 | 63373204 |
Periodontitis | 14.83 | 9.76 | 22 | 100582 | 3281 | 63385137 |
Mediastinal effusion | 14.75 | 9.76 | 5 | 100599 | 57 | 63388361 |
Urinary incontinence | 14.72 | 9.76 | 94 | 100510 | 31920 | 63356498 |
Device colour issue | 14.66 | 9.76 | 4 | 100600 | 20 | 63388398 |
Expired product administered | 14.51 | 9.76 | 31 | 100573 | 6150 | 63382268 |
Melaena | 14.51 | 9.76 | 16 | 100588 | 30349 | 63358069 |
Product outer packaging issue | 14.50 | 9.76 | 4 | 100600 | 21 | 63388397 |
Myelosuppression | 14.33 | 9.76 | 10 | 100594 | 23693 | 63364725 |
Tachycardia | 14.32 | 9.76 | 119 | 100485 | 118037 | 63270381 |
Product design issue | 14.27 | 9.76 | 3 | 100601 | 3 | 63388415 |
Vaginal prolapse | 14.21 | 9.76 | 9 | 100595 | 459 | 63387959 |
Cold urticaria | 14.18 | 9.76 | 6 | 100598 | 130 | 63388288 |
Tenderness | 14.14 | 9.76 | 72 | 100532 | 22506 | 63365912 |
Poikiloderma | 14.08 | 9.76 | 7 | 100597 | 222 | 63388196 |
Foetal exposure during pregnancy | 14.03 | 9.76 | 18 | 100586 | 31944 | 63356474 |
Irritable bowel syndrome | 14.01 | 9.76 | 75 | 100529 | 82337 | 63306081 |
Injection site pain | 14.00 | 9.76 | 286 | 100318 | 129514 | 63258904 |
Inappropriate schedule of product administration | 13.96 | 9.76 | 237 | 100367 | 103728 | 63284690 |
Thyrotoxic periodic paralysis | 13.91 | 9.76 | 4 | 100600 | 25 | 63388393 |
Amnesia | 13.91 | 9.76 | 142 | 100462 | 55443 | 63332975 |
Retinal vein thrombosis | 13.83 | 9.76 | 9 | 100595 | 481 | 63387937 |
Trans-sexualism | 13.81 | 9.76 | 3 | 100601 | 4 | 63388414 |
Mood altered | 13.78 | 9.76 | 53 | 100551 | 14690 | 63373728 |
Application site pustules | 13.78 | 9.76 | 4 | 100600 | 26 | 63388392 |
Poor venous access | 13.70 | 9.76 | 53 | 100551 | 14732 | 63373686 |
Budd-Chiari syndrome | 13.69 | 9.76 | 5 | 100599 | 72 | 63388346 |
Intentional product use issue | 13.67 | 9.76 | 133 | 100471 | 127759 | 63260659 |
Vulvovaginal inflammation | 13.57 | 9.76 | 11 | 100593 | 828 | 63387590 |
Scar | 13.26 | 9.76 | 50 | 100554 | 13732 | 63374686 |
Neck pain | 13.25 | 9.76 | 168 | 100436 | 69150 | 63319268 |
Hepatic cytolysis | 13.18 | 9.76 | 4 | 100600 | 15403 | 63373015 |
Oestrogen deficiency | 13.10 | 9.76 | 6 | 100598 | 158 | 63388260 |
Weight increased | 13.02 | 9.76 | 521 | 100083 | 260271 | 63128147 |
Medication error | 13.02 | 9.76 | 41 | 100563 | 52243 | 63336175 |
Obesity | 13.01 | 9.76 | 17 | 100587 | 29935 | 63358483 |
Device physical property issue | 13.00 | 9.76 | 16 | 100588 | 1996 | 63386422 |
Lip swelling | 12.94 | 9.76 | 89 | 100515 | 30974 | 63357444 |
Post procedural cellulitis | 12.93 | 9.76 | 5 | 100599 | 85 | 63388333 |
Vertebrobasilar insufficiency | 12.86 | 9.76 | 6 | 100598 | 165 | 63388253 |
Cor pulmonale acute | 12.83 | 9.76 | 8 | 100596 | 397 | 63388021 |
Electrolyte imbalance | 12.77 | 9.76 | 8 | 100596 | 20068 | 63368350 |
Pituitary tumour recurrent | 12.77 | 9.76 | 5 | 100599 | 88 | 63388330 |
Chest discomfort | 12.76 | 9.76 | 245 | 100359 | 109724 | 63278694 |
Product administered at inappropriate site | 12.76 | 9.76 | 20 | 100584 | 3129 | 63385289 |
Application site nodule | 12.75 | 9.76 | 3 | 100601 | 7 | 63388411 |
Respiratory arrest | 12.73 | 9.76 | 20 | 100584 | 32625 | 63355793 |
Endometrial disorder | 12.62 | 9.76 | 10 | 100594 | 729 | 63387689 |
Breast cyst | 12.61 | 9.76 | 15 | 100589 | 1806 | 63386612 |
Pain | 12.57 | 9.76 | 1007 | 99597 | 739621 | 62648797 |
Infusion site swelling | 12.52 | 9.76 | 39 | 100565 | 9731 | 63378687 |
Limb injury | 12.46 | 9.76 | 76 | 100528 | 25401 | 63363017 |
Heliotrope rash | 12.35 | 9.76 | 6 | 100598 | 181 | 63388237 |
Premature delivery | 12.34 | 9.76 | 18 | 100586 | 30263 | 63358155 |
Neck injury | 12.33 | 9.76 | 16 | 100588 | 2105 | 63386313 |
Sedation | 12.28 | 9.76 | 27 | 100577 | 38782 | 63349636 |
Pulmonary embolism | 12.22 | 9.76 | 256 | 100348 | 116428 | 63271990 |
Blood oestrogen abnormal | 12.20 | 9.76 | 3 | 100601 | 9 | 63388409 |
Application site laceration | 12.20 | 9.76 | 3 | 100601 | 9 | 63388409 |
Breast swelling | 12.16 | 9.76 | 13 | 100591 | 1393 | 63387025 |
Adnexa uteri pain | 12.15 | 9.76 | 8 | 100596 | 436 | 63387982 |
Muscle tightness | 12.14 | 9.76 | 44 | 100560 | 11856 | 63376562 |
Blood pressure abnormal | 12.11 | 9.76 | 52 | 100552 | 15146 | 63373272 |
Application site scab | 12.08 | 9.76 | 6 | 100598 | 190 | 63388228 |
Liver disorder | 12.07 | 9.76 | 44 | 100560 | 53643 | 63334775 |
Product use complaint | 11.86 | 9.76 | 17 | 100587 | 2457 | 63385961 |
Hypogonadism | 11.83 | 9.76 | 5 | 100599 | 108 | 63388310 |
Product storage error | 11.79 | 9.76 | 51 | 100553 | 14905 | 63373513 |
Tandem gait test abnormal | 11.77 | 9.76 | 4 | 100600 | 46 | 63388372 |
Limb discomfort | 11.71 | 9.76 | 84 | 100520 | 29632 | 63358786 |
Gingival recession | 11.70 | 9.76 | 13 | 100591 | 1454 | 63386964 |
External ear disorder | 11.69 | 9.76 | 4 | 100600 | 47 | 63388371 |
Intercepted product prescribing error | 11.69 | 9.76 | 6 | 100598 | 204 | 63388214 |
Eye irritation | 11.68 | 9.76 | 67 | 100537 | 21904 | 63366514 |
Candida infection | 11.68 | 9.76 | 81 | 100523 | 28270 | 63360148 |
XIth nerve injury | 11.61 | 9.76 | 4 | 100600 | 48 | 63388370 |
Disseminated intravascular coagulation | 11.57 | 9.76 | 8 | 100596 | 19043 | 63369375 |
Exposure keratitis | 11.54 | 9.76 | 4 | 100600 | 49 | 63388369 |
Eosinophilic pleural effusion | 11.54 | 9.76 | 4 | 100600 | 49 | 63388369 |
Ultrasound liver abnormal | 11.47 | 9.76 | 4 | 100600 | 50 | 63388368 |
Tracheal pain | 11.47 | 9.76 | 4 | 100600 | 50 | 63388368 |
Rotator cuff syndrome | 11.39 | 9.76 | 47 | 100557 | 13455 | 63374963 |
Pelvic pain | 11.35 | 9.76 | 47 | 100557 | 13472 | 63374946 |
Parotid gland enlargement | 11.31 | 9.76 | 10 | 100594 | 848 | 63387570 |
Encephalopathy | 11.31 | 9.76 | 28 | 100576 | 38592 | 63349826 |
Uterine disorder | 11.31 | 9.76 | 19 | 100585 | 3150 | 63385268 |
Suspected product quality issue | 11.30 | 9.76 | 6 | 100598 | 219 | 63388199 |
Product dispensing error | 11.29 | 9.76 | 39 | 100565 | 10266 | 63378152 |
Agranulocytosis | 11.19 | 9.76 | 14 | 100590 | 25120 | 63363298 |
Pain in extremity | 11.18 | 9.76 | 637 | 99967 | 330849 | 63057569 |
Blood testosterone decreased | 11.12 | 9.76 | 4 | 100600 | 55 | 63388363 |
Dry eye | 11.11 | 9.76 | 106 | 100498 | 40655 | 63347763 |
Acne | 11.08 | 9.76 | 69 | 100535 | 23224 | 63365194 |
Alanine aminotransferase abnormal | 11.05 | 9.76 | 23 | 100581 | 4481 | 63383937 |
Musculoskeletal discomfort | 11.04 | 9.76 | 57 | 100547 | 17910 | 63370508 |
Hyperglycaemia | 11.02 | 9.76 | 32 | 100572 | 41835 | 63346583 |
Low turnover osteopathy | 11.02 | 9.76 | 22 | 100582 | 4163 | 63384255 |
Respiratory depression | 10.99 | 9.76 | 47 | 100557 | 13668 | 63374750 |
Meningioma surgery | 10.99 | 9.76 | 4 | 100600 | 57 | 63388361 |
Procedural pain | 10.97 | 9.76 | 65 | 100539 | 21504 | 63366914 |
Product physical consistency issue | 10.96 | 9.76 | 9 | 100595 | 690 | 63387728 |
Pneumonia aspiration | 10.95 | 9.76 | 24 | 100580 | 34516 | 63353902 |
Full blood count abnormal | 10.94 | 9.76 | 21 | 100583 | 31696 | 63356722 |
Xanthoma | 10.93 | 9.76 | 4 | 100600 | 58 | 63388360 |
Posterior reversible encephalopathy syndrome | 10.91 | 9.76 | 7 | 100597 | 17338 | 63371080 |
Frontotemporal dementia | 10.89 | 9.76 | 7 | 100597 | 366 | 63388052 |
Tachypnoea | 10.86 | 9.76 | 7 | 100597 | 17295 | 63371123 |
Muscle atrophy | 10.85 | 9.76 | 30 | 100574 | 7003 | 63381415 |
Carpal tunnel decompression | 10.83 | 9.76 | 10 | 100594 | 898 | 63387520 |
Application site haemorrhage | 10.81 | 9.76 | 11 | 100593 | 1113 | 63387305 |
Transferrin decreased | 10.79 | 9.76 | 6 | 100598 | 240 | 63388178 |
Adenomyosis | 10.77 | 9.76 | 8 | 100596 | 530 | 63387888 |
Breast disorder female | 10.76 | 9.76 | 5 | 100599 | 136 | 63388282 |
Neck surgery | 10.76 | 9.76 | 14 | 100590 | 1846 | 63386572 |
Orthostatic hypotension | 10.76 | 9.76 | 26 | 100578 | 36134 | 63352284 |
Product prescribing issue | 10.74 | 9.76 | 17 | 100587 | 2682 | 63385736 |
Cystitis interstitial | 10.73 | 9.76 | 13 | 100591 | 1595 | 63386823 |
Acute hepatic failure | 10.73 | 9.76 | 8 | 100596 | 18319 | 63370099 |
Gingival ulceration | 10.62 | 9.76 | 10 | 100594 | 920 | 63387498 |
Hyperlipidaemia | 10.61 | 9.76 | 60 | 100544 | 19511 | 63368907 |
Impatience | 10.59 | 9.76 | 7 | 100597 | 384 | 63388034 |
Product residue present | 10.57 | 9.76 | 21 | 100583 | 3958 | 63384460 |
Atrial fibrillation | 10.57 | 9.76 | 126 | 100478 | 116510 | 63271908 |
Hepatic rupture | 10.57 | 9.76 | 4 | 100600 | 64 | 63388354 |
Hypervolaemia | 10.52 | 9.76 | 18 | 100586 | 28395 | 63360023 |
Neurotoxicity | 10.50 | 9.76 | 7 | 100597 | 16983 | 63371435 |
Productive cough | 10.48 | 9.76 | 58 | 100546 | 63150 | 63325268 |
Spinal disorder | 10.43 | 9.76 | 37 | 100567 | 9865 | 63378553 |
Essential hypertension | 10.42 | 9.76 | 24 | 100580 | 5009 | 63383409 |
Stress fracture | 10.40 | 9.76 | 32 | 100572 | 7931 | 63380487 |
Blister | 10.37 | 9.76 | 144 | 100460 | 129670 | 63258748 |
Accidental overdose | 10.36 | 9.76 | 13 | 100591 | 23296 | 63365122 |
Eye haematoma | 10.34 | 9.76 | 4 | 100600 | 68 | 63388350 |
Leukopenia | 10.30 | 9.76 | 176 | 100428 | 77114 | 63311304 |
Lip injury | 10.30 | 9.76 | 10 | 100594 | 956 | 63387462 |
Mammogram abnormal | 10.30 | 9.76 | 9 | 100595 | 752 | 63387666 |
Blood corticotrophin increased | 10.24 | 9.76 | 4 | 100600 | 70 | 63388348 |
Menopause | 10.16 | 9.76 | 17 | 100587 | 2808 | 63385610 |
Upper gastrointestinal haemorrhage | 10.08 | 9.76 | 9 | 100595 | 18843 | 63369575 |
Body height decreased | 10.06 | 9.76 | 37 | 100567 | 10041 | 63378377 |
Hyperthyroidism | 10.05 | 9.76 | 48 | 100556 | 14625 | 63373793 |
Iron deficiency anaemia | 10.04 | 9.76 | 60 | 100544 | 19909 | 63368509 |
Peliosis hepatis | 10.03 | 9.76 | 4 | 100600 | 74 | 63388344 |
Withdrawal syndrome | 10.00 | 9.76 | 60 | 100544 | 19937 | 63368481 |
Spider naevus | 9.96 | 9.76 | 5 | 100599 | 162 | 63388256 |
Seasonal allergy | 9.93 | 9.76 | 62 | 100542 | 20888 | 63367530 |
Increased tendency to bruise | 9.92 | 9.76 | 38 | 100566 | 10514 | 63377904 |
Benign breast neoplasm | 9.91 | 9.76 | 11 | 100593 | 1229 | 63387189 |
Vaginal ulceration | 9.90 | 9.76 | 7 | 100597 | 429 | 63387989 |
Tongue erythema | 9.87 | 9.76 | 7 | 100597 | 431 | 63387987 |
Facial asymmetry | 9.86 | 9.76 | 9 | 100595 | 796 | 63387622 |
Toothache | 9.85 | 9.76 | 58 | 100546 | 19141 | 63369277 |
Repetitive strain injury | 9.85 | 9.76 | 5 | 100599 | 166 | 63388252 |
Fall | 9.79 | 9.76 | 515 | 100089 | 391819 | 62996599 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Meningioma | 140.91 | 40.55 | 26 | 1020 | 1410 | 34954475 |
Off label use | 68.06 | 40.55 | 72 | 974 | 419452 | 34536433 |
Invasive ductal breast carcinoma | 60.24 | 40.55 | 8 | 1038 | 45 | 34955840 |
Keratoconus | 53.25 | 40.55 | 8 | 1038 | 119 | 34955766 |
Foetal exposure during pregnancy | 50.52 | 40.55 | 24 | 1022 | 38077 | 34917808 |
Product use issue | 49.68 | 40.55 | 28 | 1018 | 63188 | 34892697 |
Gynaecomastia | 47.80 | 40.55 | 16 | 1030 | 10164 | 34945721 |
Prolactin-producing pituitary tumour | 45.61 | 40.55 | 6 | 1040 | 31 | 34955854 |
Hyperprolactinaemia | 43.54 | 40.55 | 10 | 1036 | 1586 | 34954299 |
Oestradiol increased | 42.04 | 40.55 | 6 | 1040 | 61 | 34955824 |
Premature baby | 40.92 | 40.55 | 17 | 1029 | 19616 | 34936269 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Product adhesion issue | 1415.18 | 10.57 | 357 | 73872 | 2347 | 79667812 |
Meningioma | 532.33 | 10.57 | 186 | 74043 | 4112 | 79666047 |
Application site rash | 415.77 | 10.57 | 130 | 74099 | 2002 | 79668157 |
Hot flush | 359.93 | 10.57 | 342 | 73887 | 54535 | 79615624 |
Vulvovaginal discomfort | 264.46 | 10.57 | 89 | 74140 | 1749 | 79668410 |
Application site pruritus | 257.75 | 10.57 | 106 | 74123 | 3704 | 79666455 |
Application site erythema | 240.34 | 10.57 | 110 | 74119 | 5000 | 79665159 |
Product quality issue | 208.29 | 10.57 | 204 | 74025 | 33736 | 79636423 |
Death | 175.04 | 10.57 | 162 | 74067 | 566352 | 79103807 |
Application site irritation | 172.81 | 10.57 | 64 | 74165 | 1680 | 79668479 |
Vulvovaginal pain | 161.39 | 10.57 | 65 | 74164 | 2150 | 79668009 |
Ovarian hyperstimulation syndrome | 158.97 | 10.57 | 74 | 74155 | 3497 | 79666662 |
Vaginal haemorrhage | 141.12 | 10.57 | 135 | 74094 | 21682 | 79648477 |
Toxicity to various agents | 135.54 | 10.57 | 116 | 74113 | 421424 | 79248735 |
Acute kidney injury | 132.31 | 10.57 | 174 | 74055 | 519230 | 79150929 |
Menopausal symptoms | 130.70 | 10.57 | 54 | 74175 | 1909 | 79668250 |
Pneumonia viral | 121.35 | 10.57 | 86 | 74143 | 9072 | 79661087 |
Vulvovaginal burning sensation | 116.26 | 10.57 | 47 | 74182 | 1570 | 79668589 |
Hysterectomy | 112.24 | 10.57 | 71 | 74158 | 6201 | 79663958 |
Colitis microscopic | 111.07 | 10.57 | 87 | 74142 | 10681 | 79659478 |
Migraine | 110.91 | 10.57 | 249 | 73980 | 87244 | 79582915 |
Headache | 109.30 | 10.57 | 1006 | 73223 | 652766 | 79017393 |
Vulvovaginal dryness | 104.98 | 10.57 | 48 | 74181 | 2176 | 79667983 |
Febrile neutropenia | 101.41 | 10.57 | 44 | 74185 | 230955 | 79439204 |
Application site reaction | 97.69 | 10.57 | 34 | 74195 | 742 | 79669417 |
Drug abuse | 97.38 | 10.57 | 17 | 74212 | 162674 | 79507485 |
Neutropenia | 95.08 | 10.57 | 77 | 74152 | 287633 | 79382526 |
Breast tenderness | 94.80 | 10.57 | 45 | 74184 | 2223 | 79667936 |
Vaginal discharge | 94.10 | 10.57 | 68 | 74161 | 7395 | 79662764 |
Soft tissue disorder | 92.36 | 10.57 | 51 | 74178 | 3464 | 79666695 |
Salpingo-oophorectomy unilateral | 91.52 | 10.57 | 33 | 74196 | 801 | 79669358 |
Bronchitis | 90.91 | 10.57 | 298 | 73931 | 130346 | 79539813 |
Product physical issue | 89.27 | 10.57 | 53 | 74176 | 4132 | 79666027 |
Blood oestrogen decreased | 88.46 | 10.57 | 22 | 74207 | 135 | 79670024 |
Product complaint | 87.08 | 10.57 | 83 | 74146 | 13266 | 79656893 |
Thrombocytopenia | 82.75 | 10.57 | 75 | 74154 | 265184 | 79404975 |
Fibromyalgia | 78.07 | 10.57 | 180 | 74049 | 64160 | 79605999 |
Glaucoma | 77.77 | 10.57 | 94 | 74135 | 19667 | 79650492 |
Application site vesicles | 77.28 | 10.57 | 34 | 74195 | 1406 | 79668753 |
Device adhesion issue | 76.97 | 10.57 | 59 | 74170 | 7016 | 79663143 |
Sinusitis fungal | 75.18 | 10.57 | 39 | 74190 | 2335 | 79667824 |
Postmenopausal haemorrhage | 74.84 | 10.57 | 34 | 74195 | 1518 | 79668641 |
Feeling abnormal | 73.97 | 10.57 | 319 | 73910 | 158880 | 79511279 |
Product substitution issue | 72.71 | 10.57 | 92 | 74137 | 20164 | 79649995 |
Skin reaction | 72.52 | 10.57 | 82 | 74147 | 15986 | 79654173 |
Diverticulitis | 72.47 | 10.57 | 143 | 74086 | 45793 | 79624366 |
Oestrogen receptor assay positive | 72.28 | 10.57 | 22 | 74207 | 308 | 79669851 |
Cardiac arrest | 72.06 | 10.57 | 35 | 74194 | 172061 | 79498098 |
Application site pain | 70.93 | 10.57 | 48 | 74181 | 4699 | 79665460 |
Wrong technique in product usage process | 69.94 | 10.57 | 188 | 74041 | 73687 | 79596472 |
Breast cancer | 69.55 | 10.57 | 118 | 74111 | 33663 | 79636496 |
Hyperkalaemia | 68.35 | 10.57 | 12 | 74217 | 114386 | 79555773 |
Application site burn | 68.35 | 10.57 | 27 | 74202 | 848 | 79669311 |
Sepsis | 67.71 | 10.57 | 91 | 74138 | 269337 | 79400822 |
Pancytopenia | 67.46 | 10.57 | 35 | 74194 | 165710 | 79504449 |
Application site urticaria | 65.03 | 10.57 | 19 | 74210 | 229 | 79669930 |
Depression | 63.79 | 10.57 | 382 | 73847 | 216408 | 79453751 |
Multiple organ dysfunction syndrome | 62.95 | 10.57 | 17 | 74212 | 120229 | 79549930 |
Cardiac failure | 62.57 | 10.57 | 33 | 74196 | 154809 | 79515350 |
Hypotension | 62.43 | 10.57 | 206 | 74023 | 440111 | 79230048 |
Device use issue | 61.33 | 10.57 | 36 | 74193 | 2748 | 79667411 |
Sinusitis | 61.08 | 10.57 | 350 | 73879 | 195151 | 79475008 |
Progesterone receptor assay positive | 60.65 | 10.57 | 18 | 74211 | 230 | 79669929 |
Vulvovaginal pruritus | 60.52 | 10.57 | 35 | 74194 | 2598 | 79667561 |
Device material issue | 60.51 | 10.57 | 18 | 74211 | 232 | 79669927 |
Thyroid disorder | 60.41 | 10.57 | 70 | 74159 | 14009 | 79656150 |
Vaginal infection | 59.55 | 10.57 | 47 | 74182 | 5833 | 79664326 |
Breast cancer in situ | 59.54 | 10.57 | 25 | 74204 | 921 | 79669238 |
Embolism venous | 58.93 | 10.57 | 41 | 74188 | 4198 | 79665961 |
Pemphigus | 58.29 | 10.57 | 11 | 74218 | 99571 | 79570588 |
Completed suicide | 57.79 | 10.57 | 87 | 74142 | 245680 | 79424479 |
Butterfly rash | 56.99 | 10.57 | 29 | 74200 | 1667 | 79668492 |
General physical health deterioration | 56.81 | 10.57 | 106 | 74123 | 275132 | 79395027 |
Respiratory symptom | 56.66 | 10.57 | 42 | 74187 | 4749 | 79665410 |
Fungal infection | 56.48 | 10.57 | 122 | 74107 | 41626 | 79628533 |
Pyrexia | 56.00 | 10.57 | 386 | 73843 | 678323 | 78991836 |
Sputum increased | 55.81 | 10.57 | 41 | 74188 | 4572 | 79665587 |
Hand deformity | 55.72 | 10.57 | 14 | 74215 | 103905 | 79566254 |
Oestradiol increased | 55.34 | 10.57 | 14 | 74215 | 93 | 79670066 |
Bladder prolapse | 55.30 | 10.57 | 27 | 74202 | 1420 | 79668739 |
Platelet count decreased | 54.98 | 10.57 | 60 | 74169 | 194604 | 79475555 |
Incorrect dose administered by product | 53.94 | 10.57 | 16 | 74213 | 204 | 79669955 |
Ophthalmic vein thrombosis | 52.57 | 10.57 | 16 | 74213 | 224 | 79669935 |
Anti-cyclic citrullinated peptide antibody positive | 49.06 | 10.57 | 9 | 74220 | 83134 | 79587025 |
Blood cholesterol increased | 48.69 | 10.57 | 180 | 74049 | 83540 | 79586619 |
Cardio-respiratory arrest | 48.66 | 10.57 | 20 | 74209 | 108490 | 79561669 |
Incorrect dose administered by device | 48.64 | 10.57 | 39 | 74190 | 4950 | 79665209 |
Vaginal odour | 47.33 | 10.57 | 17 | 74212 | 408 | 79669751 |
Osteopenia | 47.22 | 10.57 | 71 | 74158 | 18293 | 79651866 |
Hormone level abnormal | 47.05 | 10.57 | 27 | 74202 | 1975 | 79668184 |
Intentional overdose | 46.76 | 10.57 | 20 | 74209 | 105940 | 79564219 |
Malignant neoplasm progression | 46.65 | 10.57 | 35 | 74194 | 135955 | 79534204 |
Female genital tract fistula | 46.47 | 10.57 | 41 | 74188 | 5934 | 79664225 |
Product dose omission issue | 45.83 | 10.57 | 390 | 73839 | 247147 | 79423012 |
Respiratory failure | 45.53 | 10.57 | 61 | 74168 | 180850 | 79489309 |
Hypoglycaemia | 45.11 | 10.57 | 19 | 74210 | 101575 | 79568584 |
Septic shock | 44.23 | 10.57 | 30 | 74199 | 122771 | 79547388 |
Pericarditis | 43.93 | 10.57 | 21 | 74208 | 104215 | 79565944 |
Prolactin-producing pituitary tumour | 43.66 | 10.57 | 12 | 74217 | 114 | 79670045 |
Colitis ischaemic | 43.27 | 10.57 | 62 | 74167 | 15297 | 79654862 |
Fibrocystic breast disease | 43.15 | 10.57 | 18 | 74211 | 652 | 79669507 |
Renal impairment | 43.06 | 10.57 | 50 | 74179 | 157733 | 79512426 |
Nasal polyps | 43.01 | 10.57 | 43 | 74186 | 7284 | 79662875 |
Mucosal inflammation | 42.87 | 10.57 | 9 | 74220 | 75571 | 79594588 |
Renal failure | 41.80 | 10.57 | 77 | 74152 | 200891 | 79469268 |
Muscle spasms | 41.63 | 10.57 | 292 | 73937 | 174438 | 79495721 |
Placenta accreta | 41.58 | 10.57 | 13 | 74216 | 200 | 79669959 |
Herpes zoster | 41.28 | 10.57 | 184 | 74045 | 92899 | 79577260 |
Vulvovaginal mycotic infection | 40.96 | 10.57 | 34 | 74195 | 4532 | 79665627 |
Diverticulum | 40.32 | 10.57 | 59 | 74170 | 14837 | 79655322 |
Insomnia | 40.10 | 10.57 | 376 | 73853 | 244794 | 79425365 |
Overdose | 39.73 | 10.57 | 69 | 74160 | 184137 | 79486022 |
Wound | 39.72 | 10.57 | 30 | 74199 | 116149 | 79554010 |
Disease recurrence | 39.49 | 10.57 | 110 | 74119 | 43999 | 79626160 |
Bradycardia | 39.14 | 10.57 | 41 | 74188 | 135516 | 79534643 |
Hepatic function abnormal | 38.90 | 10.57 | 10 | 74219 | 73097 | 79597062 |
Rheumatoid factor positive | 38.67 | 10.57 | 5 | 74224 | 59834 | 79610325 |
Breast cancer female | 37.92 | 10.57 | 50 | 74179 | 11411 | 79658748 |
Eczema | 37.74 | 10.57 | 103 | 74126 | 40715 | 79629444 |
Vulvovaginal injury | 37.68 | 10.57 | 13 | 74216 | 276 | 79669883 |
Oral pain | 37.51 | 10.57 | 88 | 74141 | 31710 | 79638449 |
Gastrooesophageal reflux disease | 37.50 | 10.57 | 194 | 74035 | 104052 | 79566107 |
Influenza like illness | 37.45 | 10.57 | 149 | 74080 | 71558 | 79598601 |
Arthritis | 37.39 | 10.57 | 208 | 74021 | 114672 | 79555487 |
Rectal prolapse | 37.34 | 10.57 | 24 | 74205 | 2154 | 79668005 |
Carpal tunnel syndrome | 37.30 | 10.57 | 66 | 74163 | 19462 | 79650697 |
Osteoporosis | 37.22 | 10.57 | 123 | 74106 | 53989 | 79616170 |
Anaemia | 37.17 | 10.57 | 252 | 73977 | 444763 | 79225396 |
Gastrointestinal haemorrhage | 36.97 | 10.57 | 50 | 74179 | 147669 | 79522490 |
Arthralgia | 36.73 | 10.57 | 741 | 73488 | 571062 | 79099097 |
Lactic acidosis | 36.72 | 10.57 | 10 | 74219 | 70349 | 79599810 |
Delirium | 35.73 | 10.57 | 17 | 74212 | 84610 | 79585549 |
Vaginal erosion | 35.66 | 10.57 | 7 | 74222 | 10 | 79670149 |
Disease progression | 35.43 | 10.57 | 74 | 74155 | 184288 | 79485871 |
Liver function test abnormal | 35.31 | 10.57 | 136 | 74093 | 64339 | 79605820 |
Blood creatinine increased | 34.43 | 10.57 | 57 | 74172 | 155000 | 79515159 |
Bone density abnormal | 34.35 | 10.57 | 26 | 74203 | 3034 | 79667125 |
Keratoconus | 34.34 | 10.57 | 10 | 74219 | 119 | 79670040 |
Drug interaction | 34.22 | 10.57 | 236 | 73993 | 414947 | 79255212 |
Application site scar | 34.22 | 10.57 | 11 | 74218 | 186 | 79669973 |
Product odour abnormal | 33.94 | 10.57 | 19 | 74210 | 1325 | 79668834 |
Glossodynia | 33.67 | 10.57 | 28 | 74201 | 103309 | 79566850 |
Uterine polyp | 33.63 | 10.57 | 20 | 74209 | 1564 | 79668595 |
Hypoxia | 33.60 | 10.57 | 28 | 74201 | 103215 | 79566944 |
Breast enlargement | 33.57 | 10.57 | 20 | 74209 | 1569 | 79668590 |
Pseudoprecocious puberty | 33.45 | 10.57 | 6 | 74223 | 3 | 79670156 |
Decreased appetite | 33.22 | 10.57 | 185 | 74044 | 342233 | 79327926 |
Blood oestrogen increased | 33.08 | 10.57 | 9 | 74220 | 82 | 79670077 |
Pneumonia | 33.06 | 10.57 | 425 | 73804 | 659821 | 79010338 |
Pain in extremity | 32.94 | 10.57 | 499 | 73730 | 364039 | 79306120 |
Spinal stenosis | 32.29 | 10.57 | 55 | 74174 | 15736 | 79654423 |
Cholestasis | 32.16 | 10.57 | 5 | 74224 | 52104 | 79618055 |
Vulvovaginal erythema | 31.78 | 10.57 | 11 | 74218 | 236 | 79669923 |
Product shape issue | 31.77 | 10.57 | 8 | 74221 | 52 | 79670107 |
Spinal operation | 31.71 | 10.57 | 38 | 74191 | 7879 | 79662280 |
Duodenal ulcer perforation | 31.69 | 10.57 | 11 | 74218 | 66200 | 79603959 |
Vision blurred | 31.36 | 10.57 | 187 | 74042 | 105711 | 79564448 |
Oral herpes | 31.32 | 10.57 | 75 | 74154 | 27379 | 79642780 |
Palpitations | 30.98 | 10.57 | 213 | 74016 | 126397 | 79543762 |
Endometrial cancer | 30.87 | 10.57 | 21 | 74208 | 2073 | 79668086 |
Tricuspid valve incompetence | 30.64 | 10.57 | 61 | 74168 | 19651 | 79650508 |
Memory impairment | 30.38 | 10.57 | 193 | 74036 | 111541 | 79558618 |
Injection site pain | 30.34 | 10.57 | 216 | 74013 | 129622 | 79540537 |
Endometrial cancer stage I | 30.07 | 10.57 | 10 | 74219 | 189 | 79669970 |
Intermenstrual bleeding | 29.97 | 10.57 | 32 | 74197 | 5852 | 79664307 |
Breast mass | 29.68 | 10.57 | 34 | 74195 | 6720 | 79663439 |
Coma | 29.55 | 10.57 | 30 | 74199 | 100619 | 79569540 |
Diastolic dysfunction | 29.52 | 10.57 | 43 | 74186 | 10768 | 79659391 |
Helicobacter infection | 29.43 | 10.57 | 14 | 74215 | 69690 | 79600469 |
Systemic lupus erythematosus | 29.32 | 10.57 | 42 | 74187 | 121107 | 79549052 |
Interstitial lung disease | 29.32 | 10.57 | 37 | 74192 | 112563 | 79557596 |
Bone marrow failure | 29.16 | 10.57 | 6 | 74223 | 51101 | 79619058 |
Sleep apnoea syndrome | 28.83 | 10.57 | 87 | 74142 | 36391 | 79633768 |
Chronic sinusitis | 28.81 | 10.57 | 47 | 74182 | 12979 | 79657180 |
Endometrial stromal sarcoma | 28.67 | 10.57 | 6 | 74223 | 14 | 79670145 |
Metabolic acidosis | 28.61 | 10.57 | 21 | 74208 | 82508 | 79587651 |
Paraesthesia | 28.60 | 10.57 | 270 | 73959 | 176053 | 79494106 |
Periodontal disease | 28.16 | 10.57 | 19 | 74210 | 1851 | 79668308 |
Back pain | 28.09 | 10.57 | 418 | 73811 | 303762 | 79366397 |
Feeling hot | 27.94 | 10.57 | 120 | 74109 | 59614 | 79610545 |
Product size issue | 27.85 | 10.57 | 14 | 74215 | 784 | 79669375 |
Endometrial hyperplasia | 27.75 | 10.57 | 13 | 74216 | 623 | 79669536 |
Endometrial hypertrophy | 26.83 | 10.57 | 9 | 74220 | 175 | 79669984 |
Neutrophil count decreased | 26.47 | 10.57 | 29 | 74200 | 93930 | 79576229 |
Injection site inflammation | 26.46 | 10.57 | 25 | 74204 | 3951 | 79666208 |
Head discomfort | 26.40 | 10.57 | 48 | 74181 | 14454 | 79655705 |
Anxiety | 26.36 | 10.57 | 350 | 73879 | 248162 | 79421997 |
Tinnitus | 26.34 | 10.57 | 96 | 74133 | 44237 | 79625922 |
Burning sensation | 26.06 | 10.57 | 116 | 74113 | 58516 | 79611643 |
Weight increased | 25.93 | 10.57 | 382 | 73847 | 277004 | 79393155 |
Hiatus hernia | 25.86 | 10.57 | 63 | 74166 | 23249 | 79646910 |
Stress | 25.80 | 10.57 | 144 | 74085 | 79468 | 79590691 |
Porphyria non-acute | 25.73 | 10.57 | 13 | 74216 | 736 | 79669423 |
Vitamin D decreased | 25.57 | 10.57 | 38 | 74191 | 9687 | 79660472 |
Therapeutic response unexpected | 25.51 | 10.57 | 57 | 74172 | 19889 | 79650270 |
White blood cell count decreased | 25.33 | 10.57 | 90 | 74139 | 188198 | 79481961 |
Altered state of consciousness | 25.31 | 10.57 | 5 | 74224 | 43817 | 79626342 |
Confusional state | 25.09 | 10.57 | 183 | 74046 | 317814 | 79352345 |
Arthropathy | 24.95 | 10.57 | 83 | 74146 | 177028 | 79493131 |
Meniscus injury | 24.70 | 10.57 | 31 | 74198 | 6737 | 79663422 |
Dermatitis contact | 24.66 | 10.57 | 40 | 74189 | 10993 | 79659166 |
Pneumonia aspiration | 24.59 | 10.57 | 16 | 74213 | 66951 | 79603208 |
Melaena | 24.55 | 10.57 | 13 | 74216 | 60877 | 79609282 |
Photosensitivity reaction | 24.41 | 10.57 | 58 | 74171 | 21069 | 79649090 |
Haemoglobin decreased | 24.35 | 10.57 | 115 | 74114 | 222004 | 79448155 |
Breast pain | 24.22 | 10.57 | 34 | 74195 | 8231 | 79661928 |
Respiratory distress | 24.20 | 10.57 | 12 | 74217 | 58327 | 79611832 |
Histamine intolerance | 24.10 | 10.57 | 6 | 74223 | 37 | 79670122 |
International normalised ratio increased | 24.03 | 10.57 | 26 | 74203 | 84695 | 79585464 |
Vessel puncture site bruise | 24.01 | 10.57 | 11 | 74218 | 501 | 79669658 |
Psoriasis | 23.89 | 10.57 | 154 | 74075 | 89433 | 79580726 |
Prosopagnosia | 23.83 | 10.57 | 6 | 74223 | 39 | 79670120 |
Vaginal disorder | 23.43 | 10.57 | 11 | 74218 | 530 | 79669629 |
Osteoarthritis | 23.23 | 10.57 | 150 | 74079 | 87159 | 79583000 |
Shock | 23.08 | 10.57 | 6 | 74223 | 43542 | 79626617 |
Dyspareunia | 22.94 | 10.57 | 17 | 74212 | 1921 | 79668238 |
Blood pressure systolic abnormal | 22.87 | 10.57 | 50 | 74179 | 17197 | 79652962 |
Uterine haemorrhage | 22.74 | 10.57 | 20 | 74209 | 2883 | 79667276 |
Uterine leiomyoma | 22.70 | 10.57 | 29 | 74200 | 6414 | 79663745 |
Hypothalamo-pituitary disorder | 22.58 | 10.57 | 14 | 74215 | 1180 | 79668979 |
Lung disorder | 22.54 | 10.57 | 25 | 74204 | 80532 | 79589627 |
Application site dermatitis | 22.51 | 10.57 | 8 | 74221 | 186 | 79669973 |
Emphysema | 22.46 | 10.57 | 48 | 74181 | 16252 | 79653907 |
Intervertebral disc degeneration | 22.35 | 10.57 | 47 | 74182 | 15738 | 79654421 |
Product packaging issue | 22.17 | 10.57 | 14 | 74215 | 1219 | 79668940 |
Hyponatraemia | 21.98 | 10.57 | 88 | 74141 | 177760 | 79492399 |
Pleural effusion | 21.91 | 10.57 | 66 | 74163 | 145196 | 79524963 |
Application site hypersensitivity | 21.60 | 10.57 | 9 | 74220 | 325 | 79669834 |
Invasive ductal breast carcinoma | 21.52 | 10.57 | 27 | 74202 | 5865 | 79664294 |
Application site ulcer | 21.47 | 10.57 | 7 | 74222 | 124 | 79670035 |
Stress urinary incontinence | 21.42 | 10.57 | 16 | 74213 | 1830 | 79668329 |
Muscle tightness | 21.33 | 10.57 | 41 | 74188 | 12873 | 79657286 |
Crying | 21.15 | 10.57 | 58 | 74171 | 22985 | 79647174 |
Corticosteroid binding globulin increased | 21.15 | 10.57 | 4 | 74225 | 4 | 79670155 |
Thyroxine decreased | 21.12 | 10.57 | 12 | 74217 | 861 | 79669298 |
Limb discomfort | 21.11 | 10.57 | 73 | 74156 | 32777 | 79637382 |
Procedural pain | 21.09 | 10.57 | 58 | 74171 | 23026 | 79647133 |
Nausea | 21.00 | 10.57 | 1090 | 73139 | 956106 | 78714053 |
Prostate cancer | 20.97 | 10.57 | 3 | 74226 | 33265 | 79636894 |
Periorbital oedema | 20.91 | 10.57 | 32 | 74197 | 8370 | 79661789 |
Respiratory arrest | 20.79 | 10.57 | 14 | 74215 | 57536 | 79612623 |
Hyperglycaemia | 20.61 | 10.57 | 21 | 74208 | 70314 | 79599845 |
Dehydration | 20.46 | 10.57 | 141 | 74088 | 248046 | 79422113 |
Therapy non-responder | 20.42 | 10.57 | 34 | 74195 | 92271 | 79577888 |
Body height decreased | 20.41 | 10.57 | 32 | 74197 | 8548 | 79661611 |
Oestradiol decreased | 20.26 | 10.57 | 4 | 74225 | 6 | 79670153 |
Mood swings | 20.24 | 10.57 | 52 | 74177 | 19828 | 79650331 |
Skin irritation | 20.20 | 10.57 | 37 | 74192 | 11203 | 79658956 |
Poor venous access | 20.08 | 10.57 | 49 | 74180 | 18100 | 79652059 |
Tachypnoea | 19.96 | 10.57 | 3 | 74226 | 32060 | 79638099 |
Acute respiratory distress syndrome | 19.95 | 10.57 | 8 | 74221 | 44059 | 79626100 |
Lymphogranuloma venereum | 19.88 | 10.57 | 4 | 74225 | 7 | 79670152 |
Pituitary tumour | 19.81 | 10.57 | 13 | 74216 | 1209 | 79668950 |
Vulvovaginal swelling | 19.72 | 10.57 | 9 | 74220 | 406 | 79669753 |
Poor quality sleep | 19.69 | 10.57 | 56 | 74173 | 22666 | 79647493 |
Cystocele | 19.68 | 10.57 | 11 | 74218 | 765 | 79669394 |
Intestinal polyp | 19.57 | 10.57 | 16 | 74213 | 2088 | 79668071 |
Application site erosion | 19.49 | 10.57 | 8 | 74221 | 278 | 79669881 |
Night sweats | 19.46 | 10.57 | 98 | 74131 | 51997 | 79618162 |
Atrophic vulvovaginitis | 19.44 | 10.57 | 13 | 74216 | 1248 | 79668911 |
Ovarian atrophy | 19.39 | 10.57 | 6 | 74223 | 89 | 79670070 |
Rhabdomyolysis | 19.30 | 10.57 | 42 | 74187 | 103089 | 79567070 |
Insulin-like growth factor increased | 18.94 | 10.57 | 15 | 74214 | 1871 | 79668288 |
Thermal burn | 18.86 | 10.57 | 28 | 74201 | 7132 | 79663027 |
Encephalopathy | 18.77 | 10.57 | 21 | 74208 | 67376 | 79602783 |
Retinal vein occlusion | 18.58 | 10.57 | 19 | 74210 | 3304 | 79666855 |
Application site inflammation | 18.58 | 10.57 | 9 | 74220 | 465 | 79669694 |
Atrial fibrillation | 18.58 | 10.57 | 108 | 74121 | 197778 | 79472381 |
Drug resistance | 18.57 | 10.57 | 8 | 74221 | 42205 | 79627954 |
Product taste abnormal | 18.50 | 10.57 | 16 | 74213 | 2255 | 79667904 |
Incorrect product administration duration | 18.44 | 10.57 | 37 | 74192 | 11985 | 79658174 |
Infusion related reaction | 18.39 | 10.57 | 132 | 74097 | 230105 | 79440054 |
Breast calcifications | 18.37 | 10.57 | 11 | 74218 | 871 | 79669288 |
Ovarian failure | 18.29 | 10.57 | 10 | 74219 | 666 | 79669493 |
Fatigue | 18.26 | 10.57 | 1048 | 73181 | 928679 | 78741480 |
Skin burning sensation | 18.19 | 10.57 | 39 | 74190 | 13233 | 79656926 |
Sleep disorder due to general medical condition, insomnia type | 18.00 | 10.57 | 9 | 74220 | 43547 | 79626612 |
Drug reaction with eosinophilia and systemic symptoms | 17.91 | 10.57 | 20 | 74209 | 64224 | 79605935 |
Gender dysphoria | 17.87 | 10.57 | 5 | 74224 | 51 | 79670108 |
Expulsion of medication | 17.78 | 10.57 | 5 | 74224 | 52 | 79670107 |
Electrocardiogram QT prolonged | 17.59 | 10.57 | 36 | 74193 | 90350 | 79579809 |
Hyperhidrosis | 17.59 | 10.57 | 217 | 74012 | 151275 | 79518884 |
Low density lipoprotein increased | 17.59 | 10.57 | 30 | 74199 | 8592 | 79661567 |
Hypomagnesaemia | 17.51 | 10.57 | 11 | 74218 | 46900 | 79623259 |
Soft tissue swelling | 17.39 | 10.57 | 13 | 74216 | 1488 | 79668671 |
Tenderness | 17.39 | 10.57 | 55 | 74174 | 23587 | 79646572 |
Neck pain | 17.34 | 10.57 | 125 | 74104 | 75292 | 79594867 |
Subdural haematoma | 17.31 | 10.57 | 4 | 74225 | 31430 | 79638729 |
Wrong technique in device usage process | 17.23 | 10.57 | 20 | 74209 | 4008 | 79666151 |
Application site dryness | 17.23 | 10.57 | 7 | 74222 | 237 | 79669922 |
Pelvic infection | 17.22 | 10.57 | 8 | 74221 | 376 | 79669783 |
Mediastinal effusion | 17.21 | 10.57 | 5 | 74224 | 59 | 79670100 |
Endometriosis | 17.03 | 10.57 | 19 | 74210 | 3649 | 79666510 |
Spinal osteoarthritis | 16.95 | 10.57 | 44 | 74185 | 16883 | 79653276 |
Dermal absorption impaired | 16.94 | 10.57 | 4 | 74225 | 19 | 79670140 |
Uterine disorder | 16.88 | 10.57 | 15 | 74214 | 2192 | 79667967 |
Atypical haemolytic uraemic syndrome | 16.78 | 10.57 | 11 | 74218 | 1021 | 79669138 |
Transposition of the great vessels | 16.77 | 10.57 | 5 | 74224 | 65 | 79670094 |
Ventricular dyskinesia | 16.76 | 10.57 | 8 | 74221 | 400 | 79669759 |
Exposure during pregnancy | 16.69 | 10.57 | 44 | 74185 | 101088 | 79569071 |
Stress fracture | 16.58 | 10.57 | 25 | 74204 | 6455 | 79663704 |
Haematuria | 16.52 | 10.57 | 24 | 74205 | 68812 | 79601347 |
Breast discomfort | 16.47 | 10.57 | 8 | 74221 | 416 | 79669743 |
Upper gastrointestinal haemorrhage | 16.44 | 10.57 | 9 | 74220 | 41371 | 79628788 |
Urinary tract infection | 16.34 | 10.57 | 352 | 73877 | 274160 | 79395999 |
Rectocele | 16.23 | 10.57 | 9 | 74220 | 616 | 79669543 |
Meningioma benign | 16.04 | 10.57 | 7 | 74222 | 284 | 79669875 |
Muscle fatigue | 15.95 | 10.57 | 18 | 74211 | 3501 | 79666658 |
Hepatic cytolysis | 15.88 | 10.57 | 3 | 74226 | 27148 | 79643011 |
Oestrone increased | 15.86 | 10.57 | 3 | 74226 | 3 | 79670156 |
Pruritus | 15.82 | 10.57 | 480 | 73749 | 394168 | 79275991 |
Folliculitis | 15.70 | 10.57 | 17 | 74212 | 55363 | 79614796 |
Iron deficiency anaemia | 15.59 | 10.57 | 56 | 74173 | 25616 | 79644543 |
Cytokine release syndrome | 15.55 | 10.57 | 7 | 74222 | 35991 | 79634168 |
Disseminated intravascular coagulation | 15.44 | 10.57 | 7 | 74222 | 35835 | 79634324 |
Poor quality product administered | 15.43 | 10.57 | 18 | 74211 | 3627 | 79666532 |
Trans-sexualism | 15.40 | 10.57 | 3 | 74226 | 4 | 79670155 |
Injection site bruising | 15.22 | 10.57 | 77 | 74152 | 40925 | 79629234 |
Swelling face | 15.22 | 10.57 | 116 | 74113 | 71096 | 79599063 |
Exposure via skin contact | 15.21 | 10.57 | 7 | 74222 | 322 | 79669837 |
Neck surgery | 15.19 | 10.57 | 13 | 74216 | 1806 | 79668353 |
Toothache | 15.19 | 10.57 | 47 | 74182 | 19923 | 79650236 |
Palmar-plantar erythrodysaesthesia syndrome | 15.02 | 10.57 | 6 | 74223 | 33128 | 79637031 |
Heliotrope rash | 14.97 | 10.57 | 6 | 74223 | 196 | 79669963 |
Dizziness | 14.84 | 10.57 | 615 | 73614 | 525826 | 79144333 |
Tooth fracture | 14.80 | 10.57 | 33 | 74196 | 11497 | 79658662 |
Application site exfoliation | 14.70 | 10.57 | 8 | 74221 | 528 | 79669631 |
Breast cyst | 14.59 | 10.57 | 11 | 74218 | 1276 | 79668883 |
Vulvovaginal inflammation | 14.56 | 10.57 | 8 | 74221 | 538 | 79669621 |
Poor quality device used | 14.51 | 10.57 | 14 | 74215 | 2271 | 79667888 |
Neoplasm progression | 14.50 | 10.57 | 16 | 74213 | 51666 | 79618493 |
Pericardial effusion | 14.48 | 10.57 | 13 | 74216 | 46224 | 79623935 |
Hormone receptor positive breast cancer | 14.48 | 10.57 | 7 | 74222 | 360 | 79669799 |
Full blood count abnormal | 14.42 | 10.57 | 10 | 74219 | 40464 | 79629695 |
Hypokalaemia | 14.39 | 10.57 | 77 | 74152 | 143963 | 79526196 |
Blood pressure diastolic decreased | 14.36 | 10.57 | 61 | 74168 | 30155 | 79640004 |
Limb injury | 14.33 | 10.57 | 60 | 74169 | 29468 | 79640691 |
Illness | 14.32 | 10.57 | 83 | 74146 | 46428 | 79623731 |
Liver injury | 14.32 | 10.57 | 19 | 74210 | 56595 | 79613564 |
Myelosuppression | 14.29 | 10.57 | 10 | 74219 | 40286 | 79629873 |
Cardiogenic shock | 14.09 | 10.57 | 11 | 74218 | 41903 | 79628256 |
Paranasal sinus inflammation | 14.09 | 10.57 | 6 | 74223 | 229 | 79669930 |
Myalgia | 14.08 | 10.57 | 247 | 73982 | 185394 | 79484765 |
Pain in jaw | 13.98 | 10.57 | 82 | 74147 | 46069 | 79624090 |
Pulmonary embolism | 13.97 | 10.57 | 231 | 73998 | 171423 | 79498736 |
Haemoptysis | 13.96 | 10.57 | 19 | 74210 | 55980 | 79614179 |
Visual impairment | 13.91 | 10.57 | 139 | 74090 | 91992 | 79578167 |
Cystitis interstitial | 13.89 | 10.57 | 11 | 74218 | 1372 | 79668787 |
Poikiloderma | 13.86 | 10.57 | 7 | 74222 | 396 | 79669763 |
Pneumonitis | 13.85 | 10.57 | 22 | 74207 | 60838 | 79609321 |
Bacterial vulvovaginitis | 13.79 | 10.57 | 8 | 74221 | 597 | 79669562 |
Abdominal distension | 13.72 | 10.57 | 171 | 74058 | 119479 | 79550680 |
Breast disorder | 13.69 | 10.57 | 13 | 74216 | 2068 | 79668091 |
Frontotemporal dementia | 13.67 | 10.57 | 8 | 74221 | 607 | 79669552 |
Tachycardia | 13.67 | 10.57 | 103 | 74126 | 177665 | 79492494 |
Candida infection | 13.65 | 10.57 | 71 | 74158 | 38143 | 79632016 |
Maternal exposure during pregnancy | 13.64 | 10.57 | 73 | 74156 | 136465 | 79533694 |
Type 2 diabetes mellitus | 13.62 | 10.57 | 20 | 74209 | 57102 | 79613057 |
Benign breast neoplasm | 13.56 | 10.57 | 9 | 74220 | 853 | 79669306 |
Application site discolouration | 13.54 | 10.57 | 9 | 74220 | 855 | 79669304 |
COVID-19 | 13.50 | 10.57 | 214 | 74015 | 157460 | 79512699 |
Jaundice | 13.40 | 10.57 | 18 | 74211 | 53331 | 79616828 |
Electrolyte imbalance | 13.35 | 10.57 | 6 | 74223 | 30875 | 79639284 |
Tumour lysis syndrome | 13.27 | 10.57 | 3 | 74226 | 23936 | 79646223 |
Vaginal ulceration | 13.10 | 10.57 | 6 | 74223 | 273 | 79669886 |
Orthostatic hypotension | 13.07 | 10.57 | 20 | 74209 | 56144 | 79614015 |
Neurotoxicity | 13.02 | 10.57 | 7 | 74222 | 32511 | 79637648 |
Nipple pain | 12.97 | 10.57 | 9 | 74220 | 917 | 79669242 |
Intentional self-injury | 12.95 | 10.57 | 7 | 74222 | 32412 | 79637747 |
Right ventricular failure | 12.92 | 10.57 | 3 | 74226 | 23494 | 79646665 |
Breast hyperplasia | 12.90 | 10.57 | 5 | 74224 | 149 | 79670010 |
Retinal vein thrombosis | 12.87 | 10.57 | 8 | 74221 | 677 | 79669482 |
Libido decreased | 12.87 | 10.57 | 20 | 74209 | 5301 | 79664858 |
Vertigo | 12.84 | 10.57 | 109 | 74120 | 68973 | 79601186 |
Repetitive strain injury | 12.81 | 10.57 | 5 | 74224 | 152 | 79670007 |
Spider naevus | 12.78 | 10.57 | 5 | 74224 | 153 | 79670006 |
Spinal disorder | 12.76 | 10.57 | 29 | 74200 | 10231 | 79659928 |
Cor pulmonale acute | 12.76 | 10.57 | 8 | 74221 | 688 | 79669471 |
Gastroenteritis | 12.65 | 10.57 | 64 | 74165 | 34018 | 79636141 |
Urinary incontinence | 12.60 | 10.57 | 73 | 74156 | 40836 | 79629323 |
Agranulocytosis | 12.57 | 10.57 | 14 | 74215 | 45016 | 79625143 |
Vertebrobasilar insufficiency | 12.48 | 10.57 | 6 | 74223 | 305 | 79669854 |
Testicular cancer metastatic | 12.48 | 10.57 | 4 | 74225 | 67 | 79670092 |
Intercepted product prescribing error | 12.46 | 10.57 | 6 | 74223 | 306 | 79669853 |
Hypocalcaemia | 12.38 | 10.57 | 17 | 74212 | 49907 | 79620252 |
Inflammatory myofibroblastic tumour | 12.34 | 10.57 | 5 | 74224 | 168 | 79669991 |
Post procedural cellulitis | 12.32 | 10.57 | 4 | 74225 | 70 | 79670089 |
Pre-existing condition improved | 12.21 | 10.57 | 20 | 74209 | 5543 | 79664616 |
Application site swelling | 12.18 | 10.57 | 8 | 74221 | 745 | 79669414 |
Testicular mass | 12.16 | 10.57 | 4 | 74225 | 73 | 79670086 |
Pulmonary congestion | 12.14 | 10.57 | 5 | 74224 | 27095 | 79643064 |
Dry eye | 12.09 | 10.57 | 67 | 74162 | 36864 | 79633295 |
Obesity | 12.09 | 10.57 | 9 | 74220 | 35116 | 79635043 |
Precocious puberty | 12.05 | 10.57 | 6 | 74223 | 329 | 79669830 |
Emotional disorder | 12.02 | 10.57 | 35 | 74194 | 14352 | 79655807 |
Growth accelerated | 11.98 | 10.57 | 3 | 74226 | 19 | 79670140 |
Unresponsive to stimuli | 11.92 | 10.57 | 21 | 74208 | 55767 | 79614392 |
Hyperprolactinaemia | 11.91 | 10.57 | 18 | 74211 | 4658 | 79665501 |
Atypical femur fracture | 11.85 | 10.57 | 19 | 74210 | 5170 | 79664989 |
Withdrawal syndrome | 11.83 | 10.57 | 53 | 74176 | 26801 | 79643358 |
Pituitary tumour recurrent | 11.81 | 10.57 | 5 | 74224 | 188 | 79669971 |
Irritability | 11.76 | 10.57 | 72 | 74157 | 41072 | 79629087 |
Intraductal proliferative breast lesion | 11.73 | 10.57 | 13 | 74216 | 2478 | 79667681 |
Chest discomfort | 11.68 | 10.57 | 187 | 74042 | 137857 | 79532302 |
Breast injury | 11.68 | 10.57 | 4 | 74225 | 83 | 79670076 |
Eyelid pain | 11.68 | 10.57 | 6 | 74223 | 352 | 79669807 |
Blood bilirubin increased | 11.56 | 10.57 | 28 | 74201 | 66204 | 79603955 |
Eye swelling | 11.49 | 10.57 | 52 | 74177 | 26416 | 79643743 |
Deep vein thrombosis | 11.47 | 10.57 | 167 | 74062 | 120752 | 79549407 |
Myelodysplastic syndrome | 11.45 | 10.57 | 7 | 74222 | 30294 | 79639865 |
External ear disorder | 11.42 | 10.57 | 4 | 74225 | 89 | 79670070 |
Diabetic ketoacidosis | 11.42 | 10.57 | 9 | 74220 | 34113 | 79636046 |
Feeling cold | 11.41 | 10.57 | 55 | 74174 | 28674 | 79641485 |
Uterine haematoma | 11.37 | 10.57 | 3 | 74226 | 24 | 79670135 |
Product administration interrupted | 11.37 | 10.57 | 16 | 74213 | 3883 | 79666276 |
Injection site erythema | 11.33 | 10.57 | 117 | 74112 | 78080 | 79592079 |
Pulmonary oedema | 11.32 | 10.57 | 43 | 74186 | 88211 | 79581948 |
Increased tendency to bruise | 11.31 | 10.57 | 28 | 74201 | 10436 | 79659723 |
Blood pressure increased | 11.31 | 10.57 | 267 | 73962 | 211093 | 79459066 |
Rash maculo-papular | 11.20 | 10.57 | 22 | 74207 | 56056 | 79614103 |
Cerebral haemorrhage | 11.20 | 10.57 | 23 | 74206 | 57650 | 79612509 |
Lip injury | 11.19 | 10.57 | 9 | 74220 | 1147 | 79669012 |
Cardiac failure congestive | 11.19 | 10.57 | 82 | 74147 | 142320 | 79527839 |
Transferrin decreased | 11.18 | 10.57 | 6 | 74223 | 385 | 79669774 |
Product outer packaging issue | 11.16 | 10.57 | 3 | 74226 | 26 | 79670133 |
Surgery | 11.10 | 10.57 | 60 | 74169 | 32706 | 79637453 |
Uterine cervix stenosis | 11.07 | 10.57 | 5 | 74224 | 220 | 79669939 |
Iron binding capacity total decreased | 11.07 | 10.57 | 6 | 74223 | 393 | 79669766 |
Deep dissecting haematoma | 11.06 | 10.57 | 3 | 74226 | 27 | 79670132 |
Product colour issue | 11.05 | 10.57 | 8 | 74221 | 872 | 79669287 |
Acute myocardial infarction | 10.91 | 10.57 | 36 | 74193 | 77000 | 79593159 |
Budd-Chiari syndrome | 10.91 | 10.57 | 4 | 74225 | 102 | 79670057 |
Migraine with aura | 10.86 | 10.57 | 13 | 74216 | 2692 | 79667467 |
Incorrect dose administered | 10.80 | 10.57 | 114 | 74115 | 76516 | 79593643 |
Hospitalisation | 10.79 | 10.57 | 48 | 74181 | 94188 | 79575971 |
Hepatic rupture | 10.76 | 10.57 | 4 | 74225 | 106 | 79670053 |
Gait disturbance | 10.76 | 10.57 | 261 | 73968 | 207245 | 79462914 |
Oropharyngeal pain | 10.75 | 10.57 | 152 | 74077 | 109201 | 79560958 |
Spondylolisthesis | 10.73 | 10.57 | 14 | 74215 | 3161 | 79666998 |
Multiple use of single-use product | 10.70 | 10.57 | 8 | 74221 | 916 | 79669243 |
Sedation | 10.68 | 10.57 | 20 | 74209 | 51875 | 79618284 |
None
Source | Code | Description |
---|---|---|
ATC | G03AA14 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
ATC | G03AA17 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
ATC | G03AB08 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, sequential preparations |
ATC | G03CA03 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ESTROGENS Natural and semisynthetic estrogens, plain |
ATC | G03CA53 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ESTROGENS Natural and semisynthetic estrogens, plain |
ATC | H01CC53 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES HYPOTHALAMIC HORMONES Anti-gonadotropin-releasing hormones |
ATC | H01CC54 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES HYPOTHALAMIC HORMONES Anti-gonadotropin-releasing hormones |
FDA CS | M0447348 | Estradiol Congeners |
FDA MoA | N0000000100 | Estrogen Receptor Agonists |
MeSH PA | D004967 | Estrogens |
MeSH PA | D006728 | Hormones |
FDA EPC | N0000175825 | Estrogen |
CHEBI has role | CHEBI:50114 | estrogens |
CHEBI has role | CHEBI:62872 | quinoline oxidase inhibitors |
CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
CHEBI has role | CHEBI:83056 | Daphnia magna metabolites |
CHEBI has role | CHEBI:176497 | geroprotectors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Premenstrual dysphoric disorder | indication | 596004 | |
Contraception | indication | 13197004 | |
Female hypogonadism syndrome | indication | 16041008 | |
Atrophic vaginitis | indication | 52441000 | |
Urethral atrophy | indication | 52620003 | |
Primary ovarian failure | indication | 65846009 | |
Acne vulgaris | indication | 88616000 | |
Postmenopausal osteoporosis | indication | 102447009 | |
Ovarian deficiency symptoms | indication | 111550004 | |
Vasomotor symptoms associated with menopausal disorder | indication | 123756000 | |
Menopausal flushing | indication | 198436008 | |
Atrophic vulva | indication | 248861000 | DOID:14275 |
Hormone replacement cycle in embryo transfer | indication | 266717002 | |
Controlled ovarian stimulation | indication | 732970000 | |
Advanced Prostatic Carcinoma | indication | ||
Metastatic Prostate Carcinoma | indication | ||
Metastatic Breast Carcinoma | indication | ||
Amenorrhea | off-label use | 14302001 | DOID:13938 |
Polycystic ovaries | off-label use | 69878008 | |
Dysmenorrhea | off-label use | 266599000 | |
Postcoital contraception | off-label use | 268463003 | |
Abnormal uterine bleeding unrelated to menstrual cycle | off-label use | 312984006 | |
Menorrhagia | off-label use | 386692008 | |
Pre-Menopausal Osteoporosis | off-label use | ||
Heart valve disorder | contraindication | 368009 | DOID:4079 |
Hyperlipoproteinemia | contraindication | 3744001 | DOID:1168 |
Gynecomastia | contraindication | 4754008 | DOID:12698 |
Hypocalcemia | contraindication | 5291005 | |
Alcoholism | contraindication | 7200002 | |
Weight gain finding | contraindication | 8943002 | |
Hypercholesterolemia | contraindication | 13644009 | |
Hyperkalemia | contraindication | 14140009 | |
Jaundice | contraindication | 18165001 | |
Toxic shock syndrome | contraindication | 18504008 | DOID:14115 |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Fibroadenosis of breast | contraindication | 23260002 | DOID:10352 |
Diplopia | contraindication | 24982008 | |
Retinal hemorrhage | contraindication | 28998008 | |
Depressive disorder | contraindication | 35489007 | |
Chloasma | contraindication | 36209000 | |
Migraine | contraindication | 37796009 | DOID:6364 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
Hypothyroidism | contraindication | 40930008 | DOID:1459 |
Body fluid retention | contraindication | 43498006 | |
Thrombosis of retinal vein | contraindication | 46085004 | |
Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
Chronic heart failure | contraindication | 48447003 | |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Dementia | contraindication | 52448006 | |
Hepatic porphyria | contraindication | 55056006 | DOID:3133 |
Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
Hyperlipidemia | contraindication | 55822004 | DOID:1168 |
Heart disease | contraindication | 56265001 | DOID:114 |
Anorexia nervosa | contraindication | 56882008 | DOID:8689 |
Benign mammary dysplasia | contraindication | 57993004 | |
Acute nephropathy | contraindication | 58574008 | |
Obstructive hyperbilirubinemia | contraindication | 59848001 | |
Hepatic failure | contraindication | 59927004 | |
Cerebrovascular disease | contraindication | 62914000 | DOID:6713 |
Thrombophlebitis | contraindication | 64156001 | DOID:3875 |
Osteoporosis | contraindication | 64859006 | DOID:11476 |
Intermenstrual bleeding - irregular | contraindication | 64996003 | |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Sleep apnea | contraindication | 73430006 | DOID:0050847 |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Heart failure | contraindication | 84114007 | DOID:6000 |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Breast lump | contraindication | 89164003 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Malignant neoplasm of liver | contraindication | 93870000 | DOID:3571 |
Uterine fibroids | contraindication | 95315005 | DOID:13223 |
Neoplasm of prostate | contraindication | 126906006 | DOID:10283 |
Neoplasm of female genital organ | contraindication | 126907002 | DOID:120 |
Deep venous thrombosis | contraindication | 128053003 | |
Seizure disorder | contraindication | 128613002 | |
Endometriosis | contraindication | 129103003 | |
Bed-ridden | contraindication | 160685001 | |
Liver function tests abnormal | contraindication | 166603001 | |
Mammography abnormal | contraindication | 168750009 | |
Angina pectoris | contraindication | 194828000 | |
Asthma | contraindication | 195967001 | DOID:2841 |
Cerebrovascular accident | contraindication | 230690007 | |
Pulmonary thromboembolism | contraindication | 233935004 | |
Thrombophilia | contraindication | 234467004 | DOID:2452 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Cholestasis of pregnancy | contraindication | 235888006 | |
Metabolic syndrome X | contraindication | 237602007 | DOID:14221 |
Endometrial carcinoma | contraindication | 254878006 | DOID:2871 |
Benign prostatic hyperplasia | contraindication | 266569009 | |
Edema | contraindication | 267038008 | |
Chorea | contraindication | 271700006 | |
Pregnancy, function | contraindication | 289908002 | |
Hypertriglyceridemia | contraindication | 302870006 | |
Osteopenia | contraindication | 312894000 | |
Functional visual loss | contraindication | 313165001 | |
Non-Q wave myocardial infarction | contraindication | 314207007 | |
Malignant tumor of cervix | contraindication | 363354003 | DOID:4362 |
Malignant tumor of ovary | contraindication | 363443007 | DOID:2394 |
Thromboembolic disorder | contraindication | 371039008 | |
Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
Cardiovascular event risk | contraindication | 395112001 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Chronic lung disease | contraindication | 413839001 | |
Disorder of coronary artery | contraindication | 414024009 | |
Obesity | contraindication | 414916001 | DOID:9970 |
Estrogen receptor positive tumor | contraindication | 416053008 | |
Porphyria | contraindication | 418470004 | |
Resistance to activated protein C due to Factor V Leiden | contraindication | 421527008 | |
Optic disc edema | contraindication | 423341008 | DOID:146 |
Family history of malignant neoplasm of breast | contraindication | 429740004 | |
Hypertensive urgency | contraindication | 443482000 | |
Carcinoma of female breast | contraindication | 447782002 | |
Smokes tobacco daily | contraindication | 449868002 | |
Nonspecific Abnormal Papanicolaou Smear of Cervix | contraindication | ||
Diabetes with Vascular Disease Complication | contraindication | ||
Major Surgery with Prolonged Post-Operative Immobilization | contraindication | ||
Worsening Headache Disorder | contraindication | ||
Acute Thromboembolic Stroke | contraindication | ||
Benign Hepatic Cell Adenoma | contraindication | ||
Breast Carcinoma in Males | contraindication |
Species | Use | Relation |
---|---|---|
Cattle | To increase rate of weight gain | Indication |
Cattle | To improve feed efficiency | Indication |
Cattle | Synchronization of estrus/ovulation | Indication |
Product | Applicant | Ingredients |
---|---|---|
Compudose 200, Encore (Compudose 400 ) | Elanco US Inc. | 2 |
Component E-H with Tylan | Elanco US Inc. | 3 |
Revalor-G, Revalor-IS, Revalor-S | Intervet Inc. | 2 |
Revalor-200, Revalor-H, Revalor-IH | Intervet Inc. | 2 |
Revalor-XH, Revalor-XS | Intervet Inc. | 2 |
Revalor-XR | Intervet Inc. | 2 |
Component TE-G, Component TE-G with Tylan, Component TE-ID with Tylan, Component TE-IS, Component TE-IS with Tylan, Component TE-S, Component TE-S with Tylan | Elanco US Inc. | 3 |
Component TE-200 with Tylan, Component TE-H with Tylan, Component TE-IH with Tylan | Elanco US Inc. | 3 |
Synovex T120, Synovex T40, Synovex T80 | Zoetis Inc. | 2 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.13 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
1MG;0.5MG;40MG | MYFEMBREE | MYOVANT SCIENCES | N214846 | May 26, 2021 | RX | TABLET | ORAL | 9346822 | Feb. 17, 2024 | MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) IN PREMENOPAUSAL WOMEN |
0.025MG/24HR | MINIVELLE | NOVEN | N203752 | Sept. 23, 2014 | RX | FILM, EXTENDED RELEASE | TRANSDERMAL | 9730900 | July 10, 2028 | A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900 |
0.0375MG/24HR | MINIVELLE | NOVEN | N203752 | Oct. 29, 2012 | RX | FILM, EXTENDED RELEASE | TRANSDERMAL | 9730900 | July 10, 2028 | A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900 |
0.05MG/24HR | MINIVELLE | NOVEN | N203752 | Oct. 29, 2012 | RX | FILM, EXTENDED RELEASE | TRANSDERMAL | 9730900 | July 10, 2028 | A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900 |
0.075MG/24HR | MINIVELLE | NOVEN | N203752 | Oct. 29, 2012 | RX | FILM, EXTENDED RELEASE | TRANSDERMAL | 9730900 | July 10, 2028 | A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900 |
0.1MG/24HR | MINIVELLE | NOVEN | N203752 | Oct. 29, 2012 | RX | FILM, EXTENDED RELEASE | TRANSDERMAL | 9730900 | July 10, 2028 | A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900 |
EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE | ORIAHNN (COPACKAGED) | ABBVIE | N213388 | May 29, 2020 | RX | CAPSULE | ORAL | 11459305 | Nov. 7, 2028 | MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10537581 | Nov. 21, 2032 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10537581 | Nov. 21, 2032 | TREATMENT OF DYSPAREUNIA |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10835487 | Nov. 21, 2032 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10835487 | Nov. 21, 2032 | TREATMENT OF DYSPAREUNIA |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11241445 | Nov. 21, 2032 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11241445 | Nov. 21, 2032 | TREATMENT OF DYSPAREUNIA |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11246875 | Nov. 21, 2032 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11246875 | Nov. 21, 2032 | TREATMENT OF DYSPAREUNIA |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11351182 | Nov. 21, 2032 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11351182 | Nov. 21, 2032 | TREATMENT OF DYSPAREUNIA |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11497709 | Nov. 21, 2032 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11497709 | Nov. 21, 2032 | TREATMENT OF DYSPAREUNIA |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10537581 | Nov. 21, 2032 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10537581 | Nov. 21, 2032 | TREATMENT OF DYSPAREUNIA |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10835487 | Nov. 21, 2032 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10835487 | Nov. 21, 2032 | TREATMENT OF DYSPAREUNIA |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11241445 | Nov. 21, 2032 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11241445 | Nov. 21, 2032 | TREATMENT OF DYSPAREUNIA |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11246875 | Nov. 21, 2032 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11246875 | Nov. 21, 2032 | TREATMENT OF DYSPAREUNIA |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11351182 | Nov. 21, 2032 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11351182 | Nov. 21, 2032 | TREATMENT OF DYSPAREUNIA |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11497709 | Nov. 21, 2032 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11497709 | Nov. 21, 2032 | TREATMENT OF DYSPAREUNIA |
0.5MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Dec. 28, 2021 | DISCN | CAPSULE | ORAL | 10206932 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
0.5MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Dec. 28, 2021 | DISCN | CAPSULE | ORAL | 10675288 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
0.5MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Dec. 28, 2021 | DISCN | CAPSULE | ORAL | 11033626 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
0.5MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Dec. 28, 2021 | DISCN | CAPSULE | ORAL | 8846648 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
0.5MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Dec. 28, 2021 | DISCN | CAPSULE | ORAL | 8846649 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
0.5MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Dec. 28, 2021 | DISCN | CAPSULE | ORAL | 8933059 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
0.5MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Dec. 28, 2021 | DISCN | CAPSULE | ORAL | 9114145 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
0.5MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Dec. 28, 2021 | DISCN | CAPSULE | ORAL | 9114146 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
0.5MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Dec. 28, 2021 | DISCN | CAPSULE | ORAL | 9301920 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
1MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Oct. 28, 2018 | RX | CAPSULE | ORAL | 10206932 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
1MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Oct. 28, 2018 | RX | CAPSULE | ORAL | 10675288 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
1MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Oct. 28, 2018 | RX | CAPSULE | ORAL | 10806740 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
1MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Oct. 28, 2018 | RX | CAPSULE | ORAL | 11033626 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
1MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Oct. 28, 2018 | RX | CAPSULE | ORAL | 11103513 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
1MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Oct. 28, 2018 | RX | CAPSULE | ORAL | 8846648 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
1MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Oct. 28, 2018 | RX | CAPSULE | ORAL | 8846649 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
1MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Oct. 28, 2018 | RX | CAPSULE | ORAL | 9006222 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
1MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Oct. 28, 2018 | RX | CAPSULE | ORAL | 9114145 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
1MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Oct. 28, 2018 | RX | CAPSULE | ORAL | 9114146 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
1MG;100MG | BIJUVA | MAYNE PHARMA | N210132 | Oct. 28, 2018 | RX | CAPSULE | ORAL | 9301920 | Nov. 21, 2032 | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10471072 | June 18, 2033 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10471072 | June 18, 2033 | TREATMENT OF DYSPAREUNIA |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10568891 | June 18, 2033 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10568891 | June 18, 2033 | TREATMENT OF DYSPAREUNIA |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10668082 | June 18, 2033 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10668082 | June 18, 2033 | TREATMENT OF DYSPAREUNIA |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10888516 | June 18, 2033 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10888516 | June 18, 2033 | TREATMENT OF DYSPAREUNIA |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10471072 | June 18, 2033 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10471072 | June 18, 2033 | TREATMENT OF DYSPAREUNIA |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10568891 | June 18, 2033 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10568891 | June 18, 2033 | TREATMENT OF DYSPAREUNIA |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10668082 | June 18, 2033 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10668082 | June 18, 2033 | TREATMENT OF DYSPAREUNIA |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10888516 | June 18, 2033 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10888516 | June 18, 2033 | TREATMENT OF DYSPAREUNIA |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10258630 | Dec. 20, 2033 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10258630 | Dec. 20, 2033 | TREATMENT OF DYSPAREUNIA |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10398708 | Dec. 20, 2033 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10398708 | Dec. 20, 2033 | TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 9180091 | Dec. 20, 2033 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 9180091 | Dec. 20, 2033 | TREATMENT OF DYSPAREUNIA |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10258630 | Dec. 20, 2033 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10258630 | Dec. 20, 2033 | TREATMENT OF DYSPAREUNIA |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10398708 | Dec. 20, 2033 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 10398708 | Dec. 20, 2033 | TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 9180091 | Dec. 20, 2033 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 9180091 | Dec. 20, 2033 | TREATMENT OF DYSPAREUNIA |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11266661 | Feb. 2, 2034 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.004MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11266661 | Feb. 2, 2034 | TREATMENT OF DYSPAREUNIA |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11266661 | Feb. 2, 2034 | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY |
0.01MG | IMVEXXY | MAYNE PHARMA | N208564 | May 29, 2018 | RX | INSERT | VAGINAL | 11266661 | Feb. 2, 2034 | TREATMENT OF DYSPAREUNIA |
EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE | ORIAHNN (COPACKAGED) | ABBVIE | N213388 | May 29, 2020 | RX | CAPSULE | ORAL | 10881659 | March 14, 2034 | MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) |
EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE | ORIAHNN (COPACKAGED) | ABBVIE | N213388 | May 29, 2020 | RX | CAPSULE | ORAL | 11045470 | March 14, 2034 | MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) |
1MG;0.5MG;40MG | MYFEMBREE | MYOVANT SCIENCES | N214846 | May 26, 2021 | RX | TABLET | ORAL | 11033551 | Sept. 29, 2037 | MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) IN PREMENOPAUSAL WOMEN |
EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE | ORIAHNN (COPACKAGED) | ABBVIE | N213388 | May 29, 2020 | RX | CAPSULE | ORAL | 11690845 | Aug. 27, 2040 | MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) USING 300 MG ELAGOLIX WHILE CO-ADMINISTERING OMEPRAZOLE |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
0.1% | ESTRADIOL | CHEMO RESEARCH SL | A211783 | Aug. 10, 2022 | RX | GEL | TRANSDERMAL | April 8, 2023 | COMPETITIVE GENERIC THERAPY |
EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE | ORIAHNN (COPACKAGED) | ABBVIE | N213388 | May 29, 2020 | RX | CAPSULE | ORAL | May 29, 2023 | NEW PRODUCT |
EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE | ORIAHNN (COPACKAGED) | ABBVIE | N213388 | May 29, 2020 | RX | CAPSULE | ORAL | July 23, 2023 | NEW CHEMICAL ENTITY |
1MG;0.5MG;40MG | MYFEMBREE | MYOVANT SCIENCES | N214846 | May 26, 2021 | RX | TABLET | ORAL | May 26, 2024 | NEW PRODUCT |
1MG;0.5MG;40MG | MYFEMBREE | MYOVANT SCIENCES | N214846 | May 26, 2021 | RX | TABLET | ORAL | Aug. 5, 2025 | FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS |
1MG;0.5MG;40MG | MYFEMBREE | MYOVANT SCIENCES | N214846 | May 26, 2021 | RX | TABLET | ORAL | Dec. 18, 2025 | NEW CHEMICAL ENTITY |
1MG;0.5MG;40MG | MYFEMBREE | MYOVANT SCIENCES | N214846 | May 26, 2021 | RX | TABLET | ORAL | Jan. 27, 2026 | INFORMATION ADDED TO THE LABELING TO DESCRIBE THE RESULTS OF MVT-601-035 |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Estrogen receptor | Nuclear hormone receptor | AGONIST | EC50 | 10.30 | WOMBAT-PK | CHEMBL | |||
Aldehyde oxidase | Enzyme | IC50 | 6.54 | WOMBAT-PK | |||||
Glucocorticoid receptor | Nuclear hormone receptor | Ki | 4.73 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 4.93 | DRUG MATRIX | |||||
Androgen receptor | Nuclear hormone receptor | IC50 | 7.72 | CHEMBL | |||||
Calcium-activated potassium channel subunit alpha-1 | Ion channel | ACTIVATOR | EC50 | 5.60 | IUPHAR | ||||
Estrogen receptor beta | Nuclear hormone receptor | EC50 | 9.70 | WOMBAT-PK | |||||
G-protein coupled estrogen receptor 1 | GPCR | EC50 | 9.52 | WOMBAT-PK | |||||
Corticosteroid-binding globulin | Secreted | Ki | 5 | CHEMBL | |||||
Steryl-sulfatase | Enzyme | IC50 | 4.08 | CHEMBL | |||||
Sex hormone-binding globulin | Secreted | Kd | 8.83 | CHEMBL | |||||
Steroid hormone receptor ERR1 | Nuclear hormone receptor | IC50 | 8.44 | CHEMBL | |||||
Steroid hormone receptor ERR2 | Nuclear hormone receptor | IC50 | 8.49 | CHEMBL | |||||
Cytochrome P450 1B1 | Enzyme | Ki | 5.72 | CHEMBL | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 5.24 | DRUG MATRIX | |||||
Alpha-synuclein | Transporter | IC50 | 4.22 | CHEMBL | |||||
Androgen receptor | Transcription factor | IC50 | 6.39 | CHEMBL | |||||
Arachidonate 15-lipoxygenase | Enzyme | IC50 | 4.95 | DRUG MATRIX | |||||
Progesterone receptor | Transcription factor | Ki | 5.37 | DRUG MATRIX | |||||
Estrogen receptor | Transcription factor | IC50 | 8.72 | CHEMBL | |||||
Estrogen receptor beta | Transcription factor | IC50 | 8.77 | CHEMBL | |||||
Estrogen receptor beta | Transcription factor | IC50 | 8.64 | CHEMBL | |||||
Estrogen receptor | Transcription factor | IC50 | 8.66 | CHEMBL | |||||
Estrogen receptor | Transcription factor | IC50 | 9.45 | CHEMBL |
ID | Source |
---|---|
4021205 | VUID |
N0000148651 | NUI |
D00105 | KEGG_DRUG |
35380-71-3 | SECONDARY_CAS_RN |
4017609 | VANDF |
4021205 | VANDF |
C0014912 | UMLSCUI |
CHEBI:16469 | CHEBI |
EST | PDB_CHEM_ID |
CHEMBL135 | ChEMBL_ID |
DB00783 | DRUGBANK_ID |
D004958 | MESH_DESCRIPTOR_UI |
5757 | PUBCHEM_CID |
406 | INN_ID |
4TI98Z838E | UNII |
236859 | RXNORM |
160774 | MMSL |
18201 | MMSL |
36188 | MMSL |
4684 | MMSL |
6157 | MMSL |
73244 | MMSL |
8602 | MMSL |
d00537 | MMSL |
001265 | NDDF |
007018 | NDDF |
116070003 | SNOMEDCT_US |
126172005 | SNOMEDCT_US |
12839006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Estring | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0013-1042 | SYSTEM | 2 mg | VAGINAL | NDA | 27 sections |
Estring | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0013-2150 | RING | 2 mg | VAGINAL | NDA | 27 sections |
Estring | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0013-2150 | RING | 2 mg | VAGINAL | NDA | 27 sections |
Alora | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5885 | PATCH | 0.03 mg | TRANSDERMAL | NDA | 35 sections |
Alora | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5886 | PATCH | 0.05 mg | TRANSDERMAL | NDA | 35 sections |
Alora | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5887 | PATCH | 0.08 mg | TRANSDERMAL | NDA | 35 sections |
Alora | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5888 | PATCH | 0.10 mg | TRANSDERMAL | NDA | 35 sections |
ELESTRIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0037-4801 | GEL, METERED | 0.52 mg | TOPICAL | NDA | 33 sections |
ELESTRIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0037-4801 | GEL, METERED | 0.52 mg | TOPICAL | NDA | 33 sections |
Vivelle-Dot | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0343 | PATCH, EXTENDED RELEASE | 0.04 mg | TRANSDERMAL | NDA | 33 sections |
Vivelle-Dot | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0343 | PATCH, EXTENDED RELEASE | 0.04 mg | TRANSDERMAL | NDA | 33 sections |
Vivelle-Dot | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0344 | PATCH, EXTENDED RELEASE | 0.05 mg | TRANSDERMAL | NDA | 33 sections |
Vivelle-Dot | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0344 | PATCH, EXTENDED RELEASE | 0.05 mg | TRANSDERMAL | NDA | 33 sections |
Vivelle-Dot | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0345 | PATCH, EXTENDED RELEASE | 0.08 mg | TRANSDERMAL | NDA | 33 sections |
Vivelle-Dot | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0345 | PATCH, EXTENDED RELEASE | 0.08 mg | TRANSDERMAL | NDA | 33 sections |
Vivelle-Dot | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0346 | PATCH, EXTENDED RELEASE | 0.10 mg | TRANSDERMAL | NDA | 33 sections |
Vivelle-Dot | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0346 | PATCH, EXTENDED RELEASE | 0.10 mg | TRANSDERMAL | NDA | 33 sections |
Vivelle-Dot | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0365 | PATCH, EXTENDED RELEASE | 0.03 mg | TRANSDERMAL | NDA | 33 sections |
Vivelle-Dot | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0365 | PATCH, EXTENDED RELEASE | 0.03 mg | TRANSDERMAL | NDA | 33 sections |
Estradiol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-3223 | INSERT | 10 ug | VAGINAL | ANDA | 29 sections |
Estradiol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-3223 | INSERT | 10 ug | VAGINAL | ANDA | 29 sections |
Estradiol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-3541 | CREAM | 0.10 mg | VAGINAL | ANDA | 25 sections |
Estradiol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-3541 | CREAM | 0.10 mg | VAGINAL | ANDA | 25 sections |
Mimvey | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-5455 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 30 sections |
Estradiol Vaginal | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1518 | CREAM | 0.10 mg | VAGINAL | ANDA | 23 sections |
Vagifem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0169-5176 | INSERT | 10 ug | VAGINAL | NDA | 31 sections |
Vagifem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0169-5176 | INSERT | 10 ug | VAGINAL | NDA | 31 sections |
Estradiol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-3349 | PATCH | 0.03 mg | TRANSDERMAL | ANDA | 30 sections |
Estradiol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-3350 | PATCH | 0.05 mg | TRANSDERMAL | ANDA | 30 sections |
Estradiol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-3351 | PATCH | 0.08 mg | TRANSDERMAL | ANDA | 30 sections |